CA-S 5-13-03

=> d ibib abs hitstr 1-34

L4 ANSWER 1 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2003:42108 CAPLUS
DOCUMENT NUMBER: 138:106601
TITLE: Preparation of substituted anilinic piperidines as MCH selective antagonists
INVENTOR(S): Marzabadi, Mohammad R.; Wetzel, John; Deleon, John E.; Jiang, Yu
PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, USA
SOURCE: PCT Int. Appl., 771 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003004027	A1	20030116	WO 2002-US21063	20020703

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-899794 A 20010705
US 2002-42582 A 20020109
OTHER SOURCE(S): MARPAT 138:106601
GI



I



II

AB The title compds. [I (R1 = H, alkyl, aryl, etc.; R2 = alkyl, cyclopropyl; R3 = (un)substituted (hetero)aryl; A = H, F, Cl, Br, CN, etc.; X = O, NH; n = 0-5), II (R1 = (un)substituted (hetero)aryl; R2, A, n as above), etc.] which are selective antagonists for melanin concg. hormone-1 (MCH1) receptors, were prepd. and formulated. Thus, reacting 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide (prepn. given) with 4-chloro-3',4'-dimethylbutyrophenone in the presence of K2CO3 and NaI in DMF afforded 80% II [R1 = R1 = 3,4-Me2C6H3; R2 = iso-Pr; A = H; n = 2] which showed Ki of 3.9 nM in cloned rat MCH1 binding assay.

IT **487051-59-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted anilinic piperidines as MCH selective antagonists)

RN 487051-59-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[(1S)-3-[4-[3-[(2-methyl-1-oxopropyl)amino]phenyl]-1-piperidinyl]-1-phenylpropyl]-2-phenoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:850328 CAPLUS

DOCUMENT NUMBER: 137:363076

TITLE: Mucin synthesis inhibitors for controlling over production of mucin

INVENTOR(S): Zhou, Yuhong; Levitt, Roy C.; Nicolaides, Nicholas C.; Jones, Steve; McLane, Mike

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 37 pp., Cont.-in-part of U. S. Ser. No. 774,243.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002165244	A1	20021107	US 2001-920287	20010802
US 2001041685	A1	20011115	US 2001-774243	20010131
US 2002147216	A1	20021010	US 2001-951906	20010914
JP 2002338493	A2	20021127	JP 2001-316112	20011012
JP 2002338494	A2	20021127	JP 2001-316115	20011012
WO 2003011294	A2	20030213	WO 2002-US21315	20020802

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2000-179127P	P	20000131
US 2000-193111P	P	20000330
US 2000-230783P	P	20000907
US 2000-242134P	P	20001023
US 2000-252052P	P	20001120
US 2001-774243	A2	20010131
US 2001-918711	A2	20010801
US 2001-920287	A2	20010802
US 2001-951906	A	20010914

OTHER SOURCE(S): MARPAT 137:363076

AB The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compds. in controlling mucin over-prodn. assocd. with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases. Talniflumate inhibited mucin over prodn. in mice models of asthma.

IT **469867-28-5**, MSI 2214 **469867-31-0**, MSI 2217
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mucin synthesis inhibitors for controlling over prodn. of mucin)

RN 469867-28-5 CAPLUS

CN Benzoic acid, 2-[3-oxo-3-[2-[[3-(trifluoromethyl)phenyl]amino]-3-pyridinyl]-1-propenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Double bond geometry unknown.
Currently available stereo shown.



RN 469867-31-0 CAPLUS

CN Benzoic acid, 2-[3-oxo-3-[2-[[3-(trifluoromethyl)phenyl]amino]-3-pyridinyl]propyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:778723 CAPLUS
DOCUMENT NUMBER: 137:289013
TITLE: Mucin synthesis inhibitors and their therapeutic use
INVENTOR(S): Zhou, Yuhong; Levitt, Roy C.; Nicolaides, Nicholas C.; Jones, Stephen; McLane, Mike
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S. Ser. No. 920,287.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002147216	A1	20021010	US 2001-951906	20010914
US 2001041685	A1	20011115	US 2001-774243	20010131
US 2002165244	A1	20021107	US 2001-920287	20010802
JP 2002338494	A2	20021127	JP 2001-316115	20011012
WO 2003011294	A2	20030213	WO 2002-US21315	20020802

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2000-179127P	P	20000131
US 2000-193111P	P	20000330
US 2000-230783P	P	20000907
US 2000-242134P	P	20001023
US 2000-252052P	P	20001120
US 2001-774243	A2	20010131
US 2001-918711	A2	20010801
US 2001-920287	A2	20010802
US 2001-951906	A	20010914

AB The invention discloses methods for modulating mucin synthesis and the therapeutic application of compds. in controlling mucin over-prodn. assocd. with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases.

IT **469867-28-5**, MSI 2214 **469867-31-0**, MSI 2217
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(mucin synthesis inhibitors and therapeutic use)
RN 469867-28-5 CAPLUS
CN Benzoic acid, 2-[3-oxo-3-[2-[[3-(trifluoromethyl)phenyl]amino]-3-pyridinyl]-1-propenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Double bond geometry unknown.
Currently available stereo shown.



RN 469867-31-0 CAPLUS
CN Benzoic acid, 2-[3-oxo-3-[2-[[3-(trifluoromethyl)phenyl]amino]-3-pyridinyl]propyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:628768 CAPLUS
DOCUMENT NUMBER: 138:130777
TITLE: Synthesis and study of antimicrobial and antiinflammatory activity of 2-substituted nicotinic acid amines
AUTHOR(S): Pavlova, M. V.; Mikhalev, A. I.; Kon'shin, M. E.; Vasil'eva, M. Yu.; Mardanova, L. G.; Odegova, T. F.; Vakhrin, M. I.
CORPORATE SOURCE: State Pharmaceutical Academy, Perm, Russia
SOURCE: Pharmaceutical Chemistry Journal (Translation of Khimiko-Farmatsevticheskii Zhurnal) (2001), 35(12), 664-666
CODEN: PCJOAU; ISSN: 0091-150X
PUBLISHER: Kluwer Academic/Consultants Bureau
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The compds. 2-(4-sulfamylanilino)nicotinic acid amides were synthesized by heating 2-chloronicotinic acid amides with p-aminosulfanylamides in 50% acetic acid. The desired 2-aryloxynicotinic acid amides were prepd. via interaction of 2-chloronicotinic acid amides with phenols in DMF in the presence of anhyd. potassium carbonate. The antimicrobial and

antiinflammatory activity of these synthesized compds. were evaluated. The antiinflammatory effect of these compds. was only slightly lower compared to that or ortophen, and some of the compds. also displayed a weak antimicrobial effect.

IT **491832-88-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and antimicrobial and antiinflammatory activity of 2-substituted nicotinic acid amines)

RN 491832-88-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[4-[[(4,6-dimethyl-2-pyrimidinyl)amino]sulfonyl]phenyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT **131236-85-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis and antimicrobial and antiinflammatory activity of 2-substituted nicotinic acid amines)

RN 131236-85-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-methoxyphenoxy)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:594842 CAPLUS
DOCUMENT NUMBER: 137:154859
TITLE: Preparation of carbamoyl-substituted pyridinyl aryl ether derivatives as inhibitors of phosphodiesterase IV isozymes
INVENTOR(S): Chambers, Robert James; Magee, Thomas Victor; Marfat, Anthony
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 285 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060896	A1	20020808	WO 2001-IB2726	20011224

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003027845	A1	20030206	US 2002-66503	20020131

PRIORITY APPLN. INFO.: US 2001-265304P P 20010131
OTHER SOURCE(S): MARPAT 137:154859
GI



I



II

AB Title compds. compds. I [wherein p = 0-1, provided that when p = 0, n = 2; m = 1-3; n = 1-2; W1 and W2 = independently O, S(O)0-2, or NR3; Y = =C(R1a) or N(O)0-1; R1a = H, F, Cl, CN, NO2, (fluoro)alkyl, alkynyl, fluoroalkoxy, OR16, or (un)substituted carbamoyl; RA and RB = independently H, F, CF3, or (un)substituted (cyclo)alkyl, Ph, or benzyl; or CRARB = spiro moiety; RC and RD = the same as RA and RB except that one of them must be H; R1 and R2 = independently H, F, Cl, CN, NO2, (fluoro)alkyl, alkynyl, OR16, or (un)substituted carbamoyl; R3 = H, alkyl, Ph, benzyl, or OR16; R4, R5 and R6 = independently H, F. Cl, alkynyl, R16, OR16, SO0-2R16, COR16, CO2R16, OCOR16, CN, NO2, (un)substituted carbamoyl(oxy), ureido, carboximidoyl, aryl, heterocyclyl, etc.; or R5 and R6 taken together with the atoms to which they are attached =

(hetero)cyclyl; J1 and J2 = independently (un)substituted, (un)satd. monocyclic or fused polycyclic ring; D = (un)substituted carboxy, carbamoyl, acyl, hydroxy(alkyl), cyano(alkyl), etc.; R16 = H or (un)substituted (cyclo)alkyl, alkenyl, Ph, benzyl, or pyridyl] were prepd. as inhibitors of PDE4 (no data). For example, 2-(benzo[1,3]dioxol-5-yloxy)nicotinic acid was coupled with (4-aminomethyl-3-fluorophenoxy)acetic acid Me ester in the presence of 1-hydroxybenzotriazole.bul.H2O and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide.bul.HCl in DMF/CH2Cl2 to give the pyridinecarboxamide II (R = Me) in 38% yield. Sapon. using aq. LiOH in THF and MeOH afforded the desired acid II (R = OH) in 21% yield. I are useful in the treatment of diseases regulated by the activation and degranulation of eosinophils, esp. asthma, chronic bronchitis, and chronic obstructive pulmonary disease (no data). In addn., I may be used in combination therapy with a wide variety of other therapeutic agents.

IT **445294-90-6P 445294-92-8P 445295-02-3P**, 2-[4-[[[[2-[(Benzo[1,3]dioxol-5-yl)oxy]-5-fluoropyridin-3-yl]carbonyl]amino]methyl]-3-fluorophenoxy]propionic acid **445295-04-5P**, (R)-2-[4-[[[[2-[(Benzo[1,3]dioxol-5-yl)oxy]pyridin-3-yl]carbonyl]amino]methyl]-3-fluorophenoxy]propionic acid **445295-08-9P**, (R)-2-[3-Fluoro-4-[[[[2-(3-cyano-phenoxy)pyridin-3-yl]carbonyl]amino]methyl]phenoxy]propionic acid **445295-09-0P**, (R)-2-[4-[[[[2-[(Benzo[1,3]dioxol-5-yl)oxy]-5-fluoropyridin-3-yl]carbonyl]amino]methyl]-3-fluorophenoxy]propionic acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(PDE4 isoenzyme inhibitor; prepn. of carbamoyl-substituted pyridinyl aryl ether derivs. as inhibitors of PDE4 isoenzymes)

RN 445294-90-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[(1R)-2-amino-1-methyl-2-oxoethoxy]-2-fluorophenyl]methyl]-2-(1,3-benzodioxol-5-yloxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445294-92-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[(1R)-2-amino-1-methyl-2-oxoethoxy]-2-fluorophenyl]methyl]-2-(1,3-benzodioxol-5-yloxy)-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445295-02-3 CAPLUS
CN Propanoic acid, 2-[4-[[[[2-(1,3-benzodioxol-5-yloxy)-5-fluoro-3-pyridinyl]carbonyl]amino]methyl]-3-fluorophenoxy]- (9CI) (CA INDEX NAME)



RN 445295-04-5 CAPLUS
CN Propanoic acid, 2-[4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3-fluorophenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445295-08-9 CAPLUS
CN Propanoic acid, 2-[4-[[[[2-(3-cyanophenoxy)-3-

pyridinyl]carbonyl]amino]methyl]-3-fluorophenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445295-09-0 CAPLUS
CN Propanoic acid, 2-[4-[[[[2-(1,3-benzodioxol-5-yloxy)-5-fluoro-3-pyridinyl]carbonyl]amino]methyl]-3-fluorophenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **445294-97-3P**, [4-[[[[2-[(Benzo[1,3]dioxol-5-yl)oxy]pyridin-3-yl]carbonyl]amino]methyl]-3-fluorophenoxy]acetic acid **445294-98-4P**, 2-[4-[[[[2-[(Benzo[1,3]dioxol-5-yl)oxy]pyridin-3-yl]carbonyl]amino]methyl]-3-fluorophenoxy]propionic acid **445295-00-1P**, 2-[3-Fluoro-4-[[[[2-(4-fluorophenoxy)pyridin-3-yl]carbonyl]amino]methyl]phenoxy]propionic acid **445295-01-2P**, 2-[3-Fluoro-4-[[[[2-(3-cyano-phenoxy)pyridin-3-yl]carbonyl]amino]methyl]phenoxy]propionic acid **445295-05-6P**, (S)-2-[4-[[[[2-[(Benzo[1,3]dioxol-5-yl)oxy]pyridin-3-yl]carbonyl]amino]methyl]-3-fluorophenoxy]propionic acid **445295-13-6P**, (R)-N-[4-(1-Carbamoylethoxy)-2-fluorobenzyl]-2-(3-cyano-phenoxy)nicotinamide **445295-14-7P 445295-15-8P 445295-16-9P 445295-17-0P 445295-18-1P 445295-19-2P**, (S)-3-[4-[[[[2-[(Benzo[1,3]dioxol-5-yl)oxy]pyridin-3-yl]carbonyl]amino]methyl]-3-fluorophenoxy]-2-methylpropionic acid **445295-20-5P 445295-22-7P 445295-23-8P 445295-73-8P**, 2-[4-[[[[2-[(Benzo[1,3]dioxol-5-yl)oxy]pyridin-3-yl]carbonyl]amino]methyl]-3-fluorophenoxy]-2-methylpropionic acid **445295-74-9P**, 2-[3-Fluoro-4-[[[[2-(4-fluorophenoxy)pyridin-3-yl]carbonyl]amino]methyl]phenoxy]-2-methylpropionic acid **445295-75-0P**, 2-[4-[[[[2-(3-Cyano-phenoxy)pyridin-3-yl]carbonyl]amino]methyl]-3-fluorophenoxy]-2-methylpropionic acid **445295-79-4P**, N-[2-Fluoro-4-[1-(5-methyl-4H-1,2,4-triazol-3-yl)ethoxy]benzyl]-2-(3-methoxyphenoxy)nicotinamide **445295-81-8P**,

N-[2-Fluoro-4-(pyridin-2-ylmethoxy)benzyl]-2-(3-methoxyphenoxy)nicotinamide **445295-82-9P**, 2-[3-Fluoro-4-[[[[2-(3-nitrophenoxy)pyridin-3-yl]carbonyl]amino]methyl]phenoxy]propionic acid **445295-83-0P**, N-[2-Fluoro-4-[1-(1H-tetrazol-5-yl)ethoxy]benzyl]-2-(3-nitrophenoxy)nicotinamide **445295-84-1P**, N-[2-Fluoro-4-[1-(5-methyl-4H-1,2,4-triazol-3-yl)ethoxy]benzyl]-2-(3-nitrophenoxy)nicotinamide **445295-88-5P**, (R)-2-[4-[[[[2-(3-Methoxyphenoxy)pyridin-3-yl]carbonyl]amino]methyl]phenoxy]propionic acid **445295-89-6P**, (R)-2-[3-Fluoro-4-[[[[2-(3-methoxyphenoxy)pyridin-3-yl]carbonyl]amino]methyl]phenoxy]propionic acid **445295-90-9P**, (R)-2-[3-Fluoro-4-[[[[5-fluoro-2-(3-methoxyphenoxy)pyridin-3-yl]carbonyl]amino]methyl]phenoxy]propionic acid **445295-91-0P**, (R)-2-[4-[[[[2-(3-Nitrophenoxy)pyridin-3-yl]carbonyl]amino]methyl]phenoxy]propionic acid **445295-92-1P**, (R)-2-[4-[[[[2-(3-Chloro-4-fluorophenoxy)pyridin-3-yl]carbonyl]amino]methyl]phenoxy]propionic acid **445295-93-2P**, (R)-2-[4-[[[[2-(3,4-Difluorophenoxy)pyridin-3-yl]carbonyl]amino]methyl]phenoxy]propionic acid **445295-94-3P**, (R)-2-[4-[[[[2-(2,3-Dihydrobenzofuran-5-yloxy)pyridin-3-yl]carbonyl]amino]methyl]phenoxy]propionic acid **445295-95-4P**, (R)-2-[4-[[[[2-(2,3-Dihydrobenzofuran-6-yloxy)pyridin-3-yl]carbonyl]amino]methyl]phenoxy]propionic acid **445295-96-5P** **445295-97-6P** **445295-98-7P**, (R)-3-[4-[[[[2-[(Benzo[1,3]dioxol-5-yl)oxy]pyridin-3-yl]carbonyl]amino]methyl]-3-fluorophenoxy]-2-methylpropionic acid **445295-99-8P** **445296-00-4P** **445296-01-5P**, 2-(3-Methoxyphenoxy)-N-[4-[1-(1H-tetrazol-5-yl)ethoxy]benzyl]nicotinamide **445296-05-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PDE4 isoenzyme inhibitor; prepn. of carbamoyl-substituted pyridinyl aryl ether derivs. as inhibitors of PDE4 isoenzymes)

RN 445294-97-3 CAPLUS
CN Acetic acid, [4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3-fluorophenoxy]- (9CI) (CA INDEX NAME)



RN 445294-98-4 CAPLUS
CN Propanoic acid, 2-[4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3-fluorophenoxy]- (9CI) (CA INDEX NAME)



RN 445295-00-1 CAPLUS
CN Propanoic acid, 2-[3-fluoro-4-[[[[2-(4-fluorophenoxy)-3-pyridinyl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 445295-01-2 CAPLUS
CN Propanoic acid, 2-[4-[[[[2-(3-cyanophenoxy)-3-pyridinyl]carbonyl]amino]methyl]-3-fluorophenoxy]- (9CI) (CA INDEX NAME)



RN 445295-05-6 CAPLUS
CN Propanoic acid, 2-[4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3-fluorophenoxy]-, (2S)- (9CI) (CA INDEX

NAME)

Absolute stereochemistry.



RN 445295-13-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[(1R)-2-amino-1-methyl-2-oxoethoxy]-2-fluorophenyl]methyl]-2-(3-cyanophenoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445295-14-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-N-[[2-fluoro-4-[1-(1H-tetrazol-5-yl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 445295-15-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-N-[[2-fluoro-4-[(1R)-1-(5-methyl-1H-1,2,4-triazol-3-yl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445295-16-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-5-fluoro-N-[[2-fluoro-4-[(1R)-1-(5-methyl-1H-1,2,4-triazol-3-yl)ethoxy]phenyl]methyl]- (9CI) (CA

INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 445295-17-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-N-[[2-fluoro-4-[(1R)-2-hydroxy-1,2-dimethylpropoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445295-18-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-5-fluoro-N-[[2-fluoro-4-[(1R)-2-hydroxy-1,2-dimethylpropoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445295-19-2 CAPLUS
CN Propanoic acid, 3-[4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-

pyridinyl]carbonyl]amino]methyl]-3-fluorophenoxy]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445295-20-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-5-fluoro-N-[[2-fluoro-4-(2-pyridinylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 445295-22-7 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-5-fluoro-N-[[2-fluoro-4-(4-pyridinylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 445295-23-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-5-fluoro-N-[[2-fluoro-4-(3-pyridinylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 445295-73-8 CAPLUS
CN Propanoic acid, 2-[4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3-fluorophenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 445295-74-9 CAPLUS
CN Propanoic acid, 2-[3-fluoro-4-[[[[2-(4-fluorophenoxy)-3-pyridinyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 445295-75-0 CAPLUS
CN Propanoic acid, 2-[4-[[[[2-(3-cyanophenoxy)-3-pyridinyl]carbonyl]amino]methyl]-3-fluorophenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 445295-79-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[[2-fluoro-4-[1-(5-methyl-1H-1,2,4-triazol-3-yl)ethoxy]phenyl]methyl]-2-(3-methoxyphenoxy)- (9CI) (CA INDEX NAME)



RN 445295-81-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[[2-fluoro-4-(2-pyridinylmethoxy)phenyl]methyl]-2-(3-methoxyphenoxy)- (9CI) (CA INDEX NAME)



RN 445295-82-9 CAPLUS
CN Propanoic acid, 2-[3-fluoro-4-[[[[2-(3-nitrophenoxy)-3-pyridinyl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 445295-83-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[[2-fluoro-4-[1-(1H-tetrazol-5-yl)ethoxy]phenyl]methyl]-2-(3-nitrophenoxy)- (9CI) (CA INDEX NAME)



RN 445295-84-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[[2-fluoro-4-[1-(5-methyl-1H-1,2,4-triazol-3-yl)ethoxy]phenyl]methyl]-2-(3-nitrophenoxy)- (9CI) (CA INDEX NAME)



RN 445295-88-5 CAPLUS
CN Propanoic acid, 2-[4-[[[[2-(3-methoxyphenoxy)-3-pyridinyl]carbonyl]amino]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445295-89-6 CAPLUS
CN Propanoic acid, 2-[3-fluoro-4-[[[[2-(3-methoxyphenoxy)-3-pyridinyl]carbonyl]amino]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445295-90-9 CAPLUS
CN Propanoic acid, 2-[3-fluoro-4-[[[[5-fluoro-2-(3-methoxyphenoxy)-3-pyridinyl]carbonyl]amino]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445295-91-0 CAPLUS
CN Propanoic acid, 2-[4-[[[[2-(3-nitrophenoxy)-3-pyridinyl]carbonyl]amino]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445295-92-1 CAPLUS
CN Propanoic acid, 2-[4-[[[[2-(3-chloro-4-fluorophenoxy)-3-pyridinyl]carbonyl]amino]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445295-93-2 CAPLUS
CN Propanoic acid, 2-[4-[[[[2-(3,4-difluorophenoxy)-3-pyridinyl]carbonyl]amino]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445295-94-3 CAPLUS
CN Propanoic acid, 2-[4-[[[[2-[(2,3-dihydro-5-benzofuranyl)oxy]-3-pyridinyl]carbonyl]amino]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445295-95-4 CAPLUS
CN Propanoic acid, 2-[4-[[[[2-[(2,3-dihydro-6-benzofuranyl)oxy]-3-pyridinyl]carbonyl]amino]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445295-96-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-N-[[2-fluoro-4-[(1S)-1-(1H-tetrazol-5-yl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445295-97-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-N-[[2-fluoro-4-[(1R)-1-(1H-tetrazol-5-yl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445295-98-7 CAPLUS
CN Propanoic acid, 3-[4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3-fluorophenoxy]-2-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445295-99-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[(2S)-3-amino-2-methyl-3-oxopropoxy]-2-fluorophenyl]methyl]-2-(1,3-benzodioxol-5-yloxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445296-00-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-5-fluoro-N-[[2-fluoro-4-[(1R)-1-(1H-tetrazol-5-yl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445296-01-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-methoxyphenoxy)-N-[[4-[1-(1H-tetrazol-5-yl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 445296-05-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-N-[[2-fluoro-4-[1-methyl-2-oxo-2-(1H-1,2,4-triazol-3-yl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **445294-76-8P**, [4-[[[[2-[(Benzo[1,3]dioxol-5-yl)oxy]pyridin-3-yl]carbonyl]amino]methyl]-3-fluorophenoxy]acetic acid methyl ester **445294-77-9P**, 2-[4-[[[[2-[(Benzo[1,3]dioxol-5-yl)oxy]pyridin-3-yl]carbonyl]amino]methyl]-3-fluorophenoxy]propionic acid tert-butyl ester **445294-79-1P**, 2-[3-Fluoro-4-[[[[2-(4-fluorophenoxy)pyridin-3-yl]carbonyl]amino]methyl]phenoxy]propionic acid tert-butyl ester **445294-80-4P**, 2-[3-Fluoro-4-[[[[2-(3-cyano-phenoxy)pyridin-3-yl]carbonyl]amino]methyl]phenoxy]propionic acid tert-butyl ester **445294-81-5P**, 2-[4-[[[[2-[(Benzo[1,3]dioxol-5-yl)oxy]-5-fluoropyridin-3-yl]carbonyl]amino]methyl]-3-fluorophenoxy]propionic acid tert-butyl ester **445294-83-7P**, (R)-2-[4-[[[[2-[(Benzo[1,3]dioxol-5-yl)oxy]pyridin-3-yl]carbonyl]amino]methyl]-3-fluorophenoxy]propionic acid methyl ester **445294-84-8P**, (S)-2-[4-[[[[2-[(Benzo[1,3]dioxol-5-yl)oxy]pyridin-3-yl]carbonyl]amino]methyl]-3-fluorophenoxy]propionic acid methyl ester **445294-86-0P**, (R)-2-[3-Fluoro-4-[[[[2-(3-cyano-phenoxy)pyridin-3-yl]carbonyl]amino]methyl]phenoxy]propionic acid methyl ester **445294-87-1P**, (R)-2-[4-[[[[2-[(Benzo[1,3]dioxol-5-yl)oxy]-5-fluoropyridin-3-yl]carbonyl]amino]methyl]-3-fluorophenoxy]propionic acid methyl ester **445294-89-3P**, (R)-2-[4-[[[[2-[(Benzo[1,3]dioxol-5-yl)oxy]pyridin-3-yl]carbonyl]amino]methyl]-3-fluorophenoxy]propionimidic acid ethyl ester **445294-91-7P** **445294-93-9P** **445294-94-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(intermediate; prepn. of carbamoyl-substituted pyridinyl aryl ether derivs. as inhibitors of PDE4 isoenzymes)

RN 445294-76-8 CAPLUS
CN Acetic acid, [4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3-fluorophenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 445294-77-9 CAPLUS
CN Propanoic acid, 2-[4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3-fluorophenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 445294-79-1 CAPLUS
CN Propanoic acid, 2-[3-fluoro-4-[[[[2-(4-fluorophenoxy)-3-pyridinyl]carbonyl]amino]methyl]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 445294-80-4 CAPLUS
CN Propanoic acid, 2-[4-[[[[2-(3-cyanophenoxy)-3-pyridinyl]carbonyl]amino]methyl]-3-fluorophenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 445294-81-5 CAPLUS
CN Propanoic acid, 2-[4-[[[[2-(1,3-benzodioxol-5-yloxy)-5-fluoro-3-pyridinyl]carbonyl]amino]methyl]-3-fluorophenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 445294-83-7 CAPLUS
CN Propanoic acid, 2-[4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-

pyridinyl]carbonyl]amino]methyl]-3-fluorophenoxy]-, methyl ester, (2R)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445294-84-8 CAPLUS
CN Propanoic acid, 2-[4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-
pyridinyl]carbonyl]amino]methyl]-3-fluorophenoxy]-, methyl ester, (2S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445294-86-0 CAPLUS
CN Propanoic acid, 2-[4-[[[[2-(3-cyanophenoxy)-3-
pyridinyl]carbonyl]amino]methyl]-3-fluorophenoxy]-, methyl ester, (2R)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445294-87-1 CAPLUS
CN Propanoic acid, 2-[4-[[[[2-(1,3-benzodioxol-5-yloxy)-5-fluoro-3-pyridinyl]carbonyl]amino]methyl]-3-fluorophenoxy]-, methyl ester, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445294-89-3 CAPLUS
CN Propanimidic acid, 2-[4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3-fluorophenoxy]-, ethyl ester, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445294-91-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[(1R)-2-amino-1-methyl-2-thioxoethoxy]-2-fluorophenyl]methyl]-2-(1,3-benzodioxol-5-yloxy)-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 445294-93-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-N-[(2-fluoro-4-hydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 445294-94-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-N-[[4-(1-cyanoethoxy)-2-fluorophenyl]methyl]- (9CI) (CA INDEX NAME)



IT **445295-21-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; prepn. of carbamoyl-substituted pyridinyl aryl ether derivs. as inhibitors of PDE4 isoenzymes)
RN 445295-21-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-5-fluoro-N-[(2-fluoro-4-hydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:594822 CAPLUS
DOCUMENT NUMBER: 137:154857
TITLE: Preparation of nicotinamide biaryl derivatives as inhibitors of PDE4 isozymes
INVENTOR(S): Chambers, Robert James; Magee, Thomas Victor; Marfat, Anthony
PATENT ASSIGNEE(S): Pfizer Productors Inc., USA
SOURCE: PCT Int. Appl., 224 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060875	A1	20020808	WO 2001-IB2341	20011206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002193612	A1	20021219	US 2002-62813	20020131

PRIORITY APPLN. INFO.: US 2001-265492P P 20010131
OTHER SOURCE(S): MARPAT 137:154857
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; g = 0-1; j = 0-1; provided that when j = 0, n must be 2; k = 0-1; m = 0-2; n = 1-2; W1 = 0, SOt (t = 0-2), NR3; W2 = OCR9R10, or absent; Y = CR1, NOk (k = 0-1); R9, R10 = H, F, CF3, etc.; or R9 and R10 are taken together, but only in the case where m = 1, to form a spiro moiety; R7, R8 have the same meaning as R9, R10 except that one of them must be H; R1, R2 = H, F, Cl, etc.; R3 = H, alkyl, Ph, etc.; R4-R6 = H, F, Cl, etc.; Q1 = Ph, benzodioxyl, etc.; Q2 = biaryl moiety], useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, esp. asthma, chronic bronchitis, and chronic obstructive pulmonary disease, were prepd. E.g., a multi-step synthesis of the amide II, starting from Me 3-bromobenzoate and 4-formylbenzeneboronic acid, was given. Compds. I showed anti-inflammatory activity at 0.0001 .mu.M to 20.0 .mu.M in whole blood assay for LTE4.

IT **445492-58-0P 445492-59-1P 445492-60-4P**
445492-61-5P 445492-75-1P 445492-76-2P
445492-77-3P 445492-78-4P 445492-79-5P
445492-80-8P 445492-81-9P 445492-82-0P
445492-83-1P 445492-84-2P 445492-85-3P
445492-86-4P 445492-87-5P 445492-88-6P
445492-89-7P 445492-90-0P 445492-91-1P
445492-95-5P 445492-96-6P 445492-97-7P
445492-98-8P 445492-99-9P 445493-00-5P
445493-01-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of biaryl nicotinamides as inhibitors of PDE4 isoenzymes)

RN 445492-58-0 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[[[[2-(4-fluorophenoxy)-3-pyridinyl]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 445492-59-1 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 445492-60-4 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3'-fluoro- (9CI) (CA INDEX NAME)



RN 445492-61-5 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[[[[2-(3-cyanophenoxy)-3-pyridinyl]carbonyl]amino]methyl]-3'-fluoro- (9CI) (CA INDEX NAME)



RN 445492-75-1 CAPLUS
CN Acetic acid, [[4'-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 445492-76-2 CAPLUS
CN Propanoic acid, 2-[[4'-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-2-fluoro[1,1'-biphenyl]-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 445492-77-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-N-[[2'-fluoro-4'-[1-(1H-tetrazol-5-yl)ethoxy][1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 445492-78-4 CAPLUS

CN Propanoic acid, 2-[[4'-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3'-fluoro[1,1'-biphenyl]-2-yl]oxy]- (9CI) (CA INDEX NAME)



RN 445492-79-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-N-[[2'-fluoro-4'-[1-(5-methyl-1H-1,2,4-triazol-3-yl)ethoxy][1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





RN 445492-80-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4'-(2-amino-1-methyl-2-oxoethoxy)-2'-fluoro[1,1'-biphenyl]-4-yl]methyl]-2-(3-cyanophenoxy)- (9CI) (CA INDEX NAME)



RN 445492-81-9 CAPLUS
CN Propanoic acid, 2-[[2,3'-difluoro-4'-[[[[2-(3-methoxyphenoxy)-3-pyridinyl]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 445492-82-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4'-(2-amino-2-oxoethyl)-3-fluoro[1,1'-biphenyl]-4-yl]methyl]-2-(1,3-benzodioxol-5-yloxy)- (9CI) (CA INDEX NAME)



RN 445492-83-1 CAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, 4'-[[[[2-(3-cyanophenoxy)-3-pyridinyl]carbonyl]amino]methyl]-3'-fluoro- (9CI) (CA INDEX NAME)



RN 445492-84-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-N-[[4'-[[(2-cyanobenzoyl)amino]methyl]-2'-fluoro[1,1'-biphenyl]-4-yl]methyl]-5-fluoro- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 445492-85-3 CAPLUS
CN 2-Pyridinecarboxamide, N-[[3'-fluoro-4'-[[[[2-(4-fluorophenoxy)-3-pyridinyl]carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 445492-86-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-N-[[2'-fluoro-4'-[1-methyl-1-(1H-tetrazol-5-yl)ethyl][1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 445492-87-5 CAPLUS

CN 3-Pyridinecarboxamide, 5-fluoro-N-[[3-fluoro-4'-[[[(5-methyl-1H-1,2,4-triazol-3-yl)carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-2-(3-methoxyphenoxy)- (9CI) (CA INDEX NAME)



RN 445492-88-6 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-N-[[2'-fluoro-4'-[[(2-methoxybenzoyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





RN 445492-89-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4'-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-2'-fluoro[1,1'-biphenyl]-4-yl]methyl]-2-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 445492-90-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[[2'-fluoro-4'-[[(1H-imidazol-4-ylcarbonyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]-2-(3-nitrophenoxy)- (9CI) (CA INDEX NAME)



RN 445492-91-1 CAPLUS
CN Butanoic acid, 3-[[4'-[[[[2-(3-chloro-4-fluorophenoxy)-3-pyridinyl]carbonyl]amino]methyl]-2-fluoro[1,1'-biphenyl]-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 445492-95-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-cyanophenoxy)-N-[[2'-fluoro-4'-[[(2-pyridinylmethyl)amino]carbonyl][1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 445492-96-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-N-[[2'-fluoro-4'-[[(2-quinolinylmethyl)amino]carbonyl][1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 445492-97-7 CAPLUS
CN 3-Pyridinecarboxamide, 5-fluoro-2-(4-fluorophenoxy)-N-[[3-fluoro-3'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 445492-98-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[[3-fluoro-4'-[[[(1-oxido-2-pyridinyl)methyl]amino]carbonyl][1,1'-biphenyl]-4-yl]methyl]-2-(3-methoxyphenoxy)- (9CI) (CA INDEX NAME)



RN 445492-99-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[[3-fluoro-4'-(2-hydroxy-1,2-dimethylpropoxy)[1,1'-biphenyl]-4-yl]methyl]-2-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 445493-00-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[[2'-fluoro-4'-(1-hydroxy-1-methylethyl)[1,1'-biphenyl]-4-yl]methyl]-2-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 445493-01-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-chloro-4-fluorophenoxy)-N-[[4'-(2-pyridinylmethoxy)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



IT **445492-68-2P 445492-69-3P 445492-70-6P**
445492-71-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of biaryl nicotinamides as inhibitors of PDE4 isoenzymes)

RN 445492-68-2 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[[[[2-(4-fluorophenoxy)-3-pyridinyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 445492-69-3 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 445492-70-6 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3'-fluoro-, methyl ester (9CI) (CA INDEX NAME)



RN 445492-71-7 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[[[[2-(3-cyanophenoxy)-3-pyridinyl]carbonyl]amino]methyl]-3'-fluoro-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:594821 CAPLUS
DOCUMENT NUMBER: 137:154856
TITLE: Preparation of N-indanyl sulfonamides as potassium channel inhibitors
INVENTOR(S): Beaudoin, Serge; Reed, Aimee D.; Gross, Michael
PATENT ASSIGNEE(S): Icagen Incorporated, USA
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060874	A1	20020808	WO 2001-US48601	20011219
WO 2002060874	C1	20030220		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002161011	A1	20021031	US 2001-4867	20011207

PRIORITY APPLN. INFO.: US 2000-256926P P 20001221
US 2001-4867 A 20011207
OTHER SOURCE(S): MARPAT 137:154856
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; A, B, D = C, N, N(O) (wherein at least one of A, B, and D is a substituted C atom and at most only one of A, B, and D is N(O)); E = H, alkyl; G = H, alkyl; or E and G taken together form a bond (site of unsatn.); R1 = H, alkyl, aryl, etc.; R2 = alkyl, aryl, heterocyclyl; R3 = H, alkyl, aryl, etc.; R4 = alkyl, aryl, heteroaryl,

etc.; R5, R6 = H, F, alkyl; or R5 and R6 taken together, along with the carbom atom to which they are both attached, form a 3-7 membered carbocyclic or heterocyclic ring; R7 = H, alkyl, OH, etc.; n = 1-3], useful as potassium channel inhibitors and esp. useful for the treatment of cardiac arrhythmias and cell proliferative disorders, were prepd. Thus, amidation of the amine II (prepn. given) with hydrocinnamoyl chloride in the presence of Et3N in THF afforded 21% III which showed 46% inhibition of Kv1.5 at 0.1 .mu.M.

IT **445402-83-5P 445402-87-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-indanyl sulfonamides as potassium channel inhibitors)

RN 445402-83-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[3-[[(4-fluorophenyl)sulfonyl]amino]-2,3-dihydro-1H-inden-5-yl]amino]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 445402-87-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[3-[[(4-ethylphenyl)sulfonyl]amino]-2,3-dihydro-1H-inden-5-yl]amino]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:591707 CAPLUS
DOCUMENT NUMBER: 137:140509
TITLE: Preparation of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isozymes
INVENTOR(S): Chambers, Robert J.; Magee, Thomas V.; Marfat, Anthony
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 180 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

EP 1229034 A1 20020807 EP 2002-250202 20020111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2002111495 A1 20020815 US 2002-62811 20020131
BR 2002000250 A 20021008 BR 2002-250 20020131
PRIORITY APPLN. INFO.: US 2001-265240P P 20010131
US 1997-43403P P 19970404
US 1998-105120P P 19981021
OTHER SOURCE(S): MARPAT 137:140509
GI



I

AB Title compds. [I; p, q = 0, 1; m = 0-2; n = 1, 2; A = CO2R7, CONR9CO2R7, CONR7R9, OP(O)(OH)2, SO3H, acylsulfonamido, etc.; W = O, S, SO, SO2, NR3; Y = N, NO, CR11; R1, R2 = H, F, Cl, cyano, NO2, alkyl, alkynyl, fluoroalkyl, etc.; R3 = H, alkyl, Ph, PhCH2, etc.; R4-R6 = H, F, Cl, alkynyl, cyano, NO2, etc.; R7 = H, (substituted) alkyl, alkenyl, alkynyl; R9 = H, alkyl, cycloalkyl, Ph, PhCH2, pyridyl, etc.; R11 = H, F, Cl, cyano, NO2, alkyl, alkynyl, fluoroalkyl, fluoroalkoxy, etc.; Ra, Rb = H, F, CF3, alkyl, (substituted) cycloalkyl, Ph, PhCH2; B1, B2 = 3-7 membered (hetero)cyclyl, 7-12 membered poly(hetero)cyclyl; pairs of variables may form rings; with provisos], were prepd. (no data). Thus, Me 2-[4-[[[2-(benzo[1,3]dioxol-5-yloxy)pyridine-3-carbonyl]amino]methyl]phenyl]-2-methylpropionate was suspended in Me3COH. Aq. NaOH was added to the suspension, and the reaction mixt. was refluxed 1 h to give 2-[4-[[[2-(benzo[1,3]dioxol-5-yloxy)pyridine-3-carbonyl]amino]methyl]phenyl]-2-methylpropionic acid.

IT **444807-05-0P 444807-06-1P 444807-07-2P**
444807-08-3P 444807-10-7P 444807-11-8P
444807-12-9P 444807-13-0P 444807-14-1P
444807-15-2P 444807-16-3P 444807-17-4P
444807-18-5P 444807-19-6P 444807-20-9P
444807-21-0P 444807-22-1P 444807-23-2P
444807-24-3P 444807-25-4P 444807-26-5P
444807-27-6P 444807-28-7P 444807-29-8P
444807-31-2P 444807-32-3P 444807-33-4P
444807-34-5P 444807-35-6P 444807-36-7P
444807-37-8P 444807-38-9P 444807-39-0P
444807-40-3P 444807-41-4P 444807-42-5P
444807-43-6P 444807-44-7P 444807-45-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compd.; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

RN 444807-05-0 CAPLUS
CN Benzeneacetic acid, 4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 444807-06-1 CAPLUS
CN Benzeneacetic acid, 4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-.alpha.,.alpha.-dimethyl-, methyl ester (9CI) (CA INDEX NAME)



RN 444807-07-2 CAPLUS
CN Benzeneacetic acid, 4-[[[[2-(4-fluorophenoxy)-3-pyridinyl]carbonyl]amino]methyl]-.alpha.,.alpha.-dimethyl-, methyl ester (9CI) (CA INDEX NAME)



RN 444807-08-3 CAPLUS
CN Benzeneacetic acid, 3-fluoro-4-[[[[2-(4-fluorophenoxy)-3-pyridinyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 444807-10-7 CAPLUS
CN Cyclobutanecarboxylic acid, 1-[4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3-fluorophenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 444807-11-8 CAPLUS

CN Cyclopropanecarboxylic acid, 1-[4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3-fluorophenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 444807-12-9 CAPLUS
CN Benzeneacetic acid, 4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3-fluoro-, methyl ester (9CI) (CA INDEX NAME)



RN 444807-13-0 CAPLUS
CN Cyclopropanecarboxylic acid, 1-[4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 444807-14-1 CAPLUS
CN Benzeneacetic acid, 4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-.alpha.,.alpha.-dimethyl- (9CI) (CA INDEX NAME)



RN 444807-15-2 CAPLUS
CN Benzeneacetic acid, 4-[[[[2-(4-fluorophenoxy)-3-pyridinyl]carbonyl]amino]methyl]-.alpha.,.alpha.-dimethyl- (9CI) (CA INDEX NAME)



RN 444807-16-3 CAPLUS
CN Cyclobutanecarboxylic acid, 1-[4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 444807-17-4 CAPLUS
CN Benzeneacetic acid, 4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3-fluoro-.alpha.,.alpha.-dimethyl- (9CI) (CA INDEX NAME)



RN 444807-18-5 CAPLUS
CN Benzeneacetic acid, 3-fluoro-4-[[[[2-(4-fluorophenoxy)-3-pyridinyl]carbonyl]amino]methyl]-.alpha.,.alpha.-dimethyl- (9CI) (CA INDEX NAME)



RN 444807-19-6 CAPLUS
CN Cyclopropanecarboxylic acid, 1-[4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 444807-20-9 CAPLUS
CN Benzeneacetic acid, 4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3-fluoro-.alpha.-methyl- (9CI) (CA INDEX NAME)



RN 444807-21-0 CAPLUS
CN Benzeneacetic acid, 4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3-methoxy-.alpha.,.alpha.-dimethyl- (9CI) (CA INDEX NAME)



RN 444807-22-1 CAPLUS
CN Benzeneacetic acid, 4-[[[[2-(1,3-benzodioxol-5-yloxy)-5-fluoro-3-pyridinyl]carbonyl]amino]methyl]-3-methoxy-.alpha.,.alpha.-dimethyl- (9CI) (CA INDEX NAME)



RN 444807-23-2 CAPLUS
CN Benzeneacetic acid, 4-[[[[2-(4-fluorophenoxy)-3-pyridinyl]carbonyl]amino]methyl]-3-methoxy-.alpha.,.alpha.-dimethyl- (9CI) (CA INDEX NAME)



RN 444807-24-3 CAPLUS
CN Benzeneacetic acid, 3-fluoro-4-[[[[2-(4-fluorophenoxy)-3-pyridinyl]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 444807-25-4 CAPLUS
CN Benzeneacetic acid, 4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 444807-26-5 CAPLUS
CN Cyclopropanecarboxylic acid, 1-[4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-

pyridinyl]carbonyl]amino]methyl]-3-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 444807-27-6 CAPLUS
CN Benzeneacetic acid, 4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 444807-28-7 CAPLUS
CN Benzeneacetic acid, 4-[[[[2-(3-cyanophenoxy)-3-pyridinyl]carbonyl]amino]methyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 444807-29-8 CAPLUS
CN Benzeneacetic acid, 4-[[[[2-(1,3-benzodioxol-5-yloxy)-5-fluoro-3-pyridinyl]carbonyl]amino]methyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 444807-31-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(2-amino-1,1-dimethyl-2-oxoethyl)phenyl]methyl]-2-(1,3-benzodioxol-5-yloxy)- (9CI) (CA INDEX NAME)



RN 444807-32-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(2-amino-2-oxoethyl)phenyl]methyl]-2-(1,3-benzodioxol-5-yloxy)- (9CI) (CA INDEX NAME)



RN 444807-33-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(2-amino-2-oxoethyl)-2-fluorophenyl]methyl]-2-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 444807-34-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(2-amino-1,1-dimethyl-2-oxoethyl)-2-fluorophenyl]methyl]-2-(1,3-benzodioxol-5-yloxy)- (9CI) (CA INDEX NAME)



RN 444807-35-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(2-amino-1,1-dimethyl-2-oxoethyl)-2-fluorophenyl]methyl]-2-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 444807-36-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[[2-fluoro-4-(1H-tetrazol-5-ylmethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 444807-37-8 CAPLUS

CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-N-[[4-[1,1-dimethyl-2-(methylamino)-2-oxoethyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 444807-38-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-N-[[4-[2-[(cyclopropylmethyl)amino]-1,1-dimethyl-2-oxoethyl]phenyl]methyl]- (9CI) (CA INDEX NAME)





RN 444807-39-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-N-[[4-[2-(ethylamino)-1,1-dimethyl-2-oxoethyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 444807-40-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[[4-(1H-tetrazol-5-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 444807-41-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[[4-[1-methyl-1-(1H-tetrazol-5-yl)ethyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 444807-42-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[[2-fluoro-4-[1-methyl-1-(1H-tetrazol-5-yl)ethyl]phenyl]methyl]-2-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 444807-43-6 CAPLUS
CN 3-Pyridinecarboxamide, 5-chloro-2-(4-fluorophenoxy)-N-[[4-[1-methyl-1-(1H-tetrazol-5-yl)ethyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 444807-44-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-5-chloro-N-[[4-[1-methyl-1-(1H-tetrazol-5-yl)ethyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 444807-45-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-N-[[4-[1-methyl-1-(1H-tetrazol-5-yl)ethyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



IT **444807-68-5P 444807-69-6P 444807-70-9P**
444807-71-0P 444807-74-3P 444807-75-4P
444807-76-5P 444807-77-6P 444807-78-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

RN 444807-68-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(1-cyano-1-methylethyl)-2-fluorophenyl]methyl]-2-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 444807-69-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(cyanomethyl)-2-fluorophenyl]methyl]-2-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 444807-70-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[(2-fluoro-4-hydroxyphenyl)methyl]-2-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 444807-71-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[(4-cyano-2-fluorophenyl)methyl]-2-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 444807-74-3 CAPLUS
CN 3-Pyridinecarboxamide, 5-chloro-2-(4-fluorophenoxy)-N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 444807-75-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-5-chloro-N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 444807-76-5 CAPLUS

CN 3-Pyridinecarboxamide, 5-chloro-N-[[4-(1-cyano-1-methylethyl)phenyl]methyl]-2-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 444807-77-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-5-chloro-N-[[4-(1-cyano-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 444807-78-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-N-[[4-(1-cyano-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:431292 CAPLUS
DOCUMENT NUMBER: 133:164438
TITLE: A new polymer-bound N-hydroxysuccinimidyl active ester linker
AUTHOR(S): Shao, Hui; Zhang, Qiang; Goodnow, Robert; Chen, Li; Tam, Steve
CORPORATE SOURCE: Department of Discovery Chemistry, Roche Research Center, Hoffmann-La Roche, Inc., Nutley, NJ, 07110, USA
SOURCE: Tetrahedron Letters (2000), 41(22), 4257-4260
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Synthesis of a new N-hydroxysuccinimidyl resin is described and the N-acylation with this resin provides amide products in high yields and excellent purities. This new linker is suitable for combinatorial library synthesis.

IT **287945-64-6P 287945-65-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of polymer-bound N-hydroxysuccinimidyl active ester linker for N-acylation)
RN 287945-64-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[(4-methoxyphenyl)methyl]-2-(4-methylphenoxy)-(9CI) (CA INDEX NAME)



RN 287945-65-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[2-(2,5-dimethoxyphenyl)ethyl]-2-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:384156 CAPLUS
DOCUMENT NUMBER: 133:30662
TITLE: Preparation of N-heteroaroyl-.beta.-alanines as .alpha.4 integrin inhibitors
INVENTOR(S): Porter, John Robert; Head, John Clifford; Warrellow, Graham John; Archibald, Sarah Catherine
PATENT ASSIGNEE(S): Celltech Therapeutics Limited, UK
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000032575	A1	20000608	WO 1999-GB3986	19991129

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,

AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1135371 A1 20010926 EP 1999-973020 19991129
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
JP 2002531439 T2 20020924 JP 2000-585217 19991129
PRIORITY APPLN. INFO.: GB 1998-26174 A 19981130
WO 1999-GB3986 W 19991129
OTHER SOURCE(S): MARPAT 133:30662
GI



II

AB R4ZZ1Z2CHR1CRR5R6 [I; R = (un)derivatized CO2H; R1 = NHR3, NHSO2R3, NHCOR3, etc.; R3 = aliph. group, (hetero)aryl, etc.; R4 = (un)substituted (hetero)aryl; R5,R6 = H, halo, alkyl, alkoxy, etc.,; Z = bond, (un)substituted (hetero)aliph. chain (sic); Z1 = bond, O, (alkyl)imino, CONH, CO2H, etc.; Z2 = (un)substituted phenylene, pyridinediyl, pyrazinediyl, etc.] were prepd. Thus, 4-(H2N)C6H4CH(NHCO2CMe3)CH2CO2Me (prepn. given) was amidated by 3,5-dichloroisonicotinoyl chloride and the deprotected product amidated by 2-chloronicotinic acid to give, after sapon., title compd. II. Data for biol. activity of I were given.

IT **273919-93-0P 273919-95-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-heteroaroyl-.beta.-alanines as .alpha.4 integrin inhibitors)

RN 273919-93-0 CAPLUS

CN Benzenepropanoic acid, 4-[(2,6-dichlorobenzoyl)amino]-.beta.-[[[2-[(2,5-dimethoxyphenyl)thio]-3-pyridinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 273919-95-2 CAPLUS

CN Benzenepropanoic acid, 4-[[(3,5-dichloro-4-pyridinyl)carbonyl]amino]-

.beta.-[[[2-[(2,5-dimethoxyphenyl)thio]-3-pyridinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:133677 CAPLUS
DOCUMENT NUMBER: 132:166229
TITLE: Substituted 1,8-naphthyridin-4(1H)-ones as phosphodiesterase 4 inhibitors
INVENTOR(S): Kleinman, Edward Fox
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000009504	A1	20000224	WO 1999-IB1390	19990805
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2340180	AA	20000224	CA 1999-2340180	19990805
AU 9949249	A1	20000306	AU 1999-49249	19990805
BR 9912902	A	20010508	BR 1999-12902	19990805
EP 1104420	A1	20010606	EP 1999-933078	19990805
EP 1104420	B1	20021218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002522541	T2	20020723	JP 2000-564956	19990805
EE 200100085	A	20020815	EE 2001-85	19990805
AT 229955	E	20030115	AT 1999-933078	19990805
US 6174895	B1	20010116	US 1999-372735	19990811
NO 2001000684	A	20010409	NO 2001-684	20010209
BG 105321	A	20011231	BG 2001-105321	20010309

PRIORITY APPLN. INFO.: US 1998-96176P P 19980811
WO 1999-IB1390 W 19990805

OTHER SOURCE(S): MARPAT 132:166229
GI



I



II

AB Title compds. I (R1, R2 = H, alkyl, cycloalkyl, aryl, heteroaryl, etc.; R3 = H, halo, OH, alkyl, alkoxy, NH2, etc.) were prepd. Thus, 2.16 g II and 0.816 g Et formate reacted in the presence of LDA in THF-hexane to give a 59% yield of I (R1 = Ph, R2 = 4-fluorophenyl, R3 = H). The prepn. of II was described.

IT **259099-08-6P 259099-09-7P 259099-10-0P**
259099-12-2P 259099-13-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(1,8-naphthyridin-4(1H)-ones as phosphodiesterase 4 inhibitors)

RN 259099-08-6 CAPLUS

CN 1-Propanone, 1-[2-[(4-fluorophenyl)amino]-3-pyridinyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 259099-09-7 CAPLUS

CN 1-Propanone, 1-[2-[(3-bromophenyl)amino]-3-pyridinyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 259099-10-0 CAPLUS

CN 1-Propanone, 1-[2-[(3-iodophenyl)amino]-3-pyridinyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 259099-12-2 CAPLUS
CN 1-Propanone, 3-(4-bromophenyl)-1-[2-[(4-fluorophenyl)amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 259099-13-3 CAPLUS
CN 1-Propanone, 3-[4-(dimethylamino)phenyl]-1-[2-[(4-fluorophenyl)amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:691085 CAPLUS
DOCUMENT NUMBER: 131:310835
TITLE: Preparation of cysteine protease inhibitors for therapeutic use
INVENTOR(S): Lubisch, Wilfried; Moller, Achim; Treiber, Hans-Jorg; Knopp, Monika
PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9954310	A2	19991028	WO 1999-EP2633	19990420
WO 9954310	A3	20000217		
W: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HR, HU, ID, IL, IN, JP, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2328396	AA	19991028	CA 1999-2328396	19990420
AU 9939276	A1	19991108	AU 1999-39276	19990420
BR 9909774	A	20001219	BR 1999-9774	19990420
EP 1073641	A2	20010207	EP 1999-922108	19990420
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO				
JP 2002512231	T2	20020423	JP 2000-544649	19990420
BG 104873	A	20010731	BG 2000-104873	20001017
NO 2000005263	A	20001019	NO 2000-5263	20001019

PRIORITY APPLN. INFO.: DE 1998-19818615 A 19980420
WO 1999-EP2633 W 19990420

OTHER SOURCE(S): MARPAT 131:310835

GI



I



II

AB The invention relates to cysteine protease inhibitors of the general formula [(I); A = -(CH2)p-R1; R1 = pyrrolidine, morpholine, piperidine, -NR5R6, (N-substituted)piperazine; R5, R6 = independently H, alkyl, cyclohexyl, cyclopentyl, (CH2)nPh, where Ph may be R6-substituted; p = 1-2; B = (substituted) Ph, pyridyl, pyrimidyl or pyridazyl; D = bond, -(CH2)m-, -CH:CH-, -C.tplbond.C-; R2 = Cl, Br, F, alkyl, NHCO alkyl, NHSO2 alkyl, NO2, -O-alkyl or NH2; R3 = alkyl which can carry a (substituted) Ph ring, indolyl ring or cyclohexyl ring; Y = Ph, pyridine, pyrimidine or pyrazine; R4 = H, COOR9 or CO-Z, where Z = NR10R11; R9,R10,R11 = (independently) H, (unsubstituted) (unbranched) alkyl; n = 0-2 and m = 0-4]. Thus, Et 2-bromo-benzoate and dimethyl(4-vinylbenzyl)amine were reacted, de-esterified, and the free acid intermediate reacted with (S)-phenylalaninol to give an intermediate which was reduced to give aldehyde (II) in 88% yield. Title compds. showed good results as inhibitors of calpain I and II or cathepsin B in a variety of in vivo and in vitro tests (no data given).

IT **247219-18-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of as cysteine protease inhibitors for therapeutic use)

RN 247219-18-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-amino-2,3-dioxo-1-(phenylmethyl)propyl]-2-[(1,2,3,4-tetrahydro-2-methyl-7-isoquinolinyl)oxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:487274 CAPLUS

DOCUMENT NUMBER: 131:116520

TITLE: Preparation of phenylalanine derivatives as pharmaceutical agents

INVENTOR(S): Head, John Clifford; Archibald, Sarah Catherine; Warrellow, Graham John; Porter, John Robert

PATENT ASSIGNEE(S): Celltech Therapeutics Limited, UK

SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9937618	A1	19990729	WO 1999-GB279	19990127
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6329372	B1	20011211	US 1999-237060	19990126
AU 9924320	A1	19990809	AU 1999-24320	19990127
EP 1051399	A1	20001115	EP 1999-903798	19990127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002501051	T2	20020115	JP 2000-528542	19990127
US 2002035127	A1	20020321	US 2001-964161	20010926

PRIORITY APPLN. INFO.:

GB 1998-1674	A	19980127
GB 1998-26669	A	19981203
US 1999-237060	A1	19990126
WO 1999-GB279	W	19990127

OTHER SOURCE(S): MARPAT 131:116520

AB Phenylalanine derivs. 4-[R1(Alk1)rL1s]C6H2RaRb(Alk2)mCHRR2NR3COHet [R is a carboxylic acid or deriv.; R1 = H, OH, alkoxy or optionally substituted cycloaliph., polycycloaliph., heterocycloaliph., polyheterocycloaliph., arom, or heteroarom. group; Alk1 = optionally substituted aliph. or

heteroaliph. chain; L1 is a linker atom or group; r, s = 0, 1; Ra, Rb = -L2(CH2)pL3Rcq, where L2, L3 = a covalent bond or linker atom or group; p = 0, 1; q = 1-3; Rc = H, halo, alkyl, OH, alkoxy, etc.; Alk2 = alkylene; m = 0, 1; R2 = H, Me; R3 = H, alkyl; Het is an optionally substituted heteroarom. group] and their salts, solvates, hydrates and N-oxides were prepd. as pharmaceutical agents. Thus, N-(2-chloronicotinoyl)-N'-(3,5-dichloro-4-picolyl)-L-4-aminophenylalanine was prepd. by coupling reaction of N-(3,5-dichloro-4-picolyl)-L-4-aminophenylalanine Me ester with 2-chloronicotinoyl chloride followed by ester hydrolysis. Title compds. were tested for inhibition of integrin-dependent cell adhesion and generally have IC50 values in the .alpha.4.beta.1 and .alpha.4.beta.7 assays of 1.mu.M and below.

IT **232617-62-8P 232617-65-1P 232617-69-5P**
232617-86-6P 232617-93-5P 232617-94-6P
232618-01-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phenylalanine derivs. as pharmaceutical agents)

RN 232617-62-8 CAPLUS

CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-N-[[2-[(2,5-dimethoxyphenyl)thio]-3-pyridinyl]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 232617-65-1 CAPLUS

CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-N-[[2-[(4-methylphenyl)thio]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 232617-69-5 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[[2-[(2,5-dimethoxyphenyl)thio]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 232617-86-6 CAPLUS
CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-N-[(2-phenoxy-3-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 232617-93-5 CAPLUS
CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[(2-phenoxy-3-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 232617-94-6 CAPLUS
CN L-Phenylalanine, 4-[[(3,5-dichloro-4-pyridinyl)carbonyl]amino]-N-[(2-phenoxy-3-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 232618-01-8 CAPLUS
CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-N-[[2-[(2,5-dimethoxyphenyl)sulfonyl]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **232617-27-5P 232617-30-0P 232617-31-1P**
232617-57-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of phenylalanine derivs. as pharmaceutical agents)
RN 232617-27-5 CAPLUS
CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-N-[[2-[(2,5-dimethoxyphenyl)thio]-3-pyridinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 232617-30-0 CAPLUS
CN L-Phenylalanine, 4-amino-N-[[2-[(2,5-dimethoxyphenyl)thio]-3-pyridinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 232617-31-1 CAPLUS
CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[[2-[(2,5-dimethoxyphenyl)thio]-3-pyridinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 232617-57-1 CAPLUS
CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-N-[[2-[(2,5-dimethoxyphenyl)sulfonyl]-3-pyridinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:788746 CAPLUS
DOCUMENT NUMBER: 130:52406
TITLE: Substituted biphenyl isoxazole sulfonamides useful as endothelin antagonists
INVENTOR(S): Murugesan, Natesan; Barrish, Joel C.; Spergel, Steven H.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: U.S., 107 pp., Cont.-in-part of U.S. Ser. No. 754,715, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5846990	A	19981208	US 1997-799616	19970213
ZA 9701423	A	19980819	ZA 1997-1423	19970219
CA 2240043	AA	19970821	CA 1997-2240043	19970220
WO 9729748	A1	19970821	WO 1997-US3956	19970220
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9722098	A1	19970902	AU 1997-22098	19970220
AU 720458	B2	20000601		
EP 921800	A1	19990616	EP 1997-915055	19970220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002500619	T2	20020108	JP 1997-529620	19970220

PRIORITY APPLN. INFO.: US 1995-493331 B2 19950724
US 1996-603975 B1 19960220
US 1996-754715 B2 19961121

US 1997-799616 A 19970213
WO 1997-US3956 W 19970220

OTHER SOURCE(S): MARPAT 130:52406
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I inhibit the activity of endothelin (no data), and are useful as antihypertensives, etc. The symbols in I are defined as follows [one of X and Y = N, other = O; J = O, S, N, (un)substituted NH; K, L = N or C, provided that at least one is C; p = 0-2; R1-R4 (bound to ring C atoms) = H, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl, aralkoxy, halo, OH, cyano, NO2, CHO, etc.; or R3R4 = (un)substituted alkylene or alkenylene; R5-R8 = groups similar to R1-R4, plus heterocyclyl, heterocyclyloxy, and others]. Over 280 synthetic examples are given. For instance, the MEM-protected, isoxazole-contg. bromide II [R = Br] was lithiated, treated with B(OPr-iso)3, and hydrolyzed to give 82% II [R = B(OH)2]. The latter was coupled with 2-(4-bromophenyl)oxazole using Pd(PPh3)4 catalyst (70%), followed by acidic deprotection of the MEM group (52%), to give title compd. III.

IT **195446-37-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted biphenyl isoxazole sulfonamides as endothelin antagonists)

RN 195446-37-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N-methyl-2-phenoxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:682365 CAPLUS
DOCUMENT NUMBER: 129:316147
TITLE: Preparation of nicotinamides as PDE4 D isoenzymes inhibitors
INVENTOR(S): Marfat, Anthony; Chambers, Robert James; Watson, John Wesley; Cheng, John Bin; Duplantier, Allen Jacob;

10/062,811

PATENT ASSIGNEE(S): Kleinman, Edward Fox
Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 200 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9845268	A1	19981015	WO 1998-IB315	19980310
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9862273	A1	19981030	AU 1998-62273	19980310
AU 738037	B2	20010906		
EP 971894	A1	20000119	EP 1998-904343	19980310
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 2000510481	T2	20000815	JP 1998-542528	19980310
BR 9810733	A	20000912	BR 1998-10733	19980310
ZA 9802853	A	19991004	ZA 1998-2853	19980403
US 6380218	B1	20020430	US 1999-308956	19990527
NO 9904791	A	19991201	NO 1999-4791	19991001
MX 9909099	A	20000228	MX 1999-9099	19991004
US 2002111495	A1	20020815	US 2002-62811	20020131

PRIORITY APPLN. INFO.:

US 1997-43403P	P	19970404
WO 1998-IB315	W	19980310
US 1998-105120P	P	19981021
US 2001-265240P	P	20010131

OTHER SOURCE(S): MARPAT 129:316147
GI



I

AB Title compds. [I; wherein m is 0 or 1; n is 0 or 1; o is 0-4; p is 0 or 1; q is 0 or 1; r is 0-4; t is 0 or 1; A is oxygen, NH, or sulfur; B is oxygen or NH; D is oxygen, NH, or alkylamino; E is CH2, O, NH, SO, SO2, S; R1 is H, alkyl, cycloalkyl, aryl, etc.; R2,R3 together with attached carbon form carbonyl group or cycloalkyl ring; R2, R3, R4 is independently H, OH, CN, CO2H, alkyl, etc.; R5 is cyclic, bicyclic, aryl; R6, R7 and R8 are each independently H, CN, COOH, NO2, OH, alkyl, etc.] and pharmaceutical compn. are prepd. for the treatment of respiratory, allergic, rheumatoid, body wt. regulation, inflammatory and central nervous system disorders such as asthma, chronic obstructive pulmonary

disease, adult respiratory diseases syndrome, shock, fibrosis, pulmonary hypersensitivity, allergic rhinitis, atopic dermatitis, psoriasis, wt. control, rheumatoid arthritis, cachexia, Crohn's disease, ulcerative colitis, arthritic conditions and other inflammatory diseases, depression, multi-infarct dementia and AIDS.

IT **111487-86-6P 214535-77-0P 214754-74-2P**
214754-75-3P 214754-76-4P 214754-80-0P
214754-81-1P 214754-82-2P 214755-34-7P
214755-36-9P 214755-37-0P 214755-41-6P
214755-45-0P 214755-46-1P 214755-50-7P
214755-51-8P 214755-53-0P 214755-54-1P
214755-55-2P 214755-56-3P 214755-57-4P
214755-58-5P 214755-59-6P 214755-60-9P
214755-61-0P 214755-62-1P 214755-67-6P
214755-71-2P 214755-73-4P 214755-75-6P
214755-76-7P 214755-78-9P 214755-81-4P
214755-83-6P 214755-84-7P 214755-86-9P
214755-87-0P 214755-88-1P 214755-89-2P
214755-92-7P 214755-93-8P 214755-94-9P
214755-95-0P 214755-98-3P 214755-99-4P
214756-00-0P 214756-01-1P 214756-06-6P
214756-07-7P 214756-12-4P 214756-25-9P
214756-71-5P 214756-73-7P 214756-74-8P
214756-78-2P 214756-81-7P 214756-82-8P
214756-85-1P 214756-86-2P 214756-87-3P
214756-93-1P 214756-95-3P 214757-06-9P
214757-12-7P 214757-13-8P 214757-14-9P
214757-15-0P 214757-17-2P 214757-18-3P
214757-19-4P 214757-21-8P 214757-22-9P
214757-23-0P 214757-24-1P 214757-26-3P
214757-27-4P 214757-28-5P 214757-29-6P
214757-34-3P 214757-35-4P 214757-38-7P
214757-40-1P 214757-41-2P 214757-42-3P
214757-43-4P 214757-44-5P 214757-45-6P
214757-46-7P 214757-47-8P 214757-50-3P
214757-52-5P 214757-55-8P 214757-58-1P
214757-62-7P 214757-68-3P 214757-69-4P
214757-70-7P 214757-71-8P 214757-74-1P
214757-75-2P 214757-76-3P 214757-78-5P
214757-80-9P 214757-81-0P 214757-82-1P
214757-83-2P 214757-84-3P 214757-85-4P
214757-88-7P 214757-89-8P 214757-90-1P
214757-91-2P 214757-92-3P 214757-93-4P
214757-94-5P 214757-95-6P 214757-96-7P
214757-97-8P 214758-00-6P 214758-01-7P
214758-03-9P 214758-10-8P 214758-14-2P
214758-15-3P 214758-17-5P 214758-18-6P
214758-20-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nicotinamides as PDE4 D isoenzymes inhibitors)

RN 111487-86-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[(2-chlorophenyl)methyl]-2-[3-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)





RN 214535-77-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214754-74-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[(1R)-1-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 214754-75-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[(1S)-1-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 214754-76-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[(2-chloro-6-fluorophenyl)methyl]-2-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 214754-80-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[(2-chlorophenyl)methyl]-2-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 214754-81-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[(2-chlorophenyl)methyl]-2-(2,4-difluorophenoxy)- (9CI) (CA INDEX NAME)



RN 214754-82-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[(2-chlorophenyl)methyl]-2-(3-fluorophenoxy)-
(9CI) (CA INDEX NAME)



RN 214755-34-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[(2,3-difluorophenyl)methyl]-2-(4-fluorophenoxy)-
(9CI) (CA INDEX NAME)



RN 214755-36-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[(3,5-difluorophenyl)methyl]-2-(4-fluorophenoxy)-
(9CI) (CA INDEX NAME)



RN 214755-37-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[(2,4,6-trifluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 214755-41-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 214755-45-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 214755-46-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[(4-hydroxy-3,5-dimethylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 214755-50-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[1-(4-bromophenyl)ethyl]-2-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 214755-51-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[[4-(1-methoxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214755-53-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[[4-(1-hydroxycyclobutyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214755-54-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[[2-chloro-4-(1-hydroxy-1-methylethyl)phenyl]methyl]-2-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 214755-55-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(1-azetidinyl)phenyl]methyl]-2-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 214755-56-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[[4-(3-hydroxy-1-azetidinyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214755-57-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[[4-(1-pyrrolidinyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214755-58-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[[4-(1-piperidinyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214755-59-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[[4-(4-morpholinyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214755-60-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[[4-(4-oxo-1-piperidinyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214755-61-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[[4-[(2-hydroxy-2-methylpropyl)methylamino]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214755-62-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[[4-(2-methyl-1,3-dioxolan-2-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214755-67-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-cyano-4-fluorophenoxy)-N-[[2-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214755-71-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[(4-hydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 214755-73-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-nitrophenoxy)-N-[[4-(2,2,2-trifluoroethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214755-75-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]-2-(3-nitrophenoxy)- (9CI) (CA INDEX NAME)



RN 214755-76-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-(3-nitrophenoxy)- (9CI) (CA INDEX NAME)



RN 214755-78-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[(2-chlorophenyl)methyl]-2-(3-cyanophenoxy)- (9CI) (CA INDEX NAME)



RN 214755-81-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-cyanophenoxy)-N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214755-83-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-cyanophenoxy)-N-[[4-(1-hydroxycyclobutyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214755-84-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[[2-chloro-4-(1-hydroxy-1-methylethyl)phenyl]methyl]-2-(3-cyanophenoxy)- (9CI) (CA INDEX NAME)



RN 214755-86-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[(2-chlorophenyl)methyl]-2-[3-(dimethylamino)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214755-87-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[(2-chlorophenyl)methyl]-2-(4-cyanophenoxy)- (9CI) (CA INDEX NAME)



RN 214755-88-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-cyanophenoxy)-N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214755-89-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[(4-aminophenyl)methyl]-2-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 214755-92-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(acetylamino)phenyl]methyl]-2-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 214755-93-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[3-(acetylamino)phenoxy]-N-[(2-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 214755-94-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[3-(acetylamino)phenoxy]-N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214755-95-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-chlorophenoxy)-N-[(1R)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 214755-98-3 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 4-[[[[2-(4-fluorophenoxy)-3-pyridinyl]carbonyl]amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 214755-99-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214756-00-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-chlorophenoxy)-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 214756-01-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-chlorophenoxy)-N-(2-hydroxy-2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 214756-06-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[(2-chlorophenyl)methyl]-2-[3-[[[(2-methoxyphenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 214756-07-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[(2-chlorophenyl)methyl]-2-[3-[[(1-naphthalenylamino)carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 214756-12-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-aminophenoxy)-N-[(2-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 214756-25-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[(2-chlorophenyl)methyl]-2-(1H-indol-4-yloxy)- (9CI) (CA INDEX NAME)



RN 214756-71-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]-2-[3-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 214756-73-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-chlorophenoxy)-N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214756-74-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-chlorophenoxy)-N-[(2-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 214756-78-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(aminosulfonyl)phenyl]methyl]-2-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 214756-81-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(aminosulfonyl)phenyl]methyl]-2-(3-cyanophenoxy)- (9CI) (CA INDEX NAME)



RN 214756-82-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(aminosulfonyl)phenyl]methyl]-2-[3-(1H-tetrazol-1-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 214756-85-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(aminosulfonyl)phenyl]methyl]-2-(3-methoxyphenoxy)- (9CI) (CA INDEX NAME)



RN 214756-86-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]-2-(3-methoxyphenoxy)- (9CI) (CA INDEX NAME)



RN 214756-87-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-fluorophenoxy)-N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214756-93-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]-2-[3-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 214756-95-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]-2-[3-(methylsulfonyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 214757-06-9 CAPLUS
CN Benzoic acid, 3-[[3-[[[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]amino]carbonyl]-2-pyridinyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 214757-12-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-acetylphenoxy)-N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214757-13-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-acetylphenoxy)-N-[(2-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 214757-14-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-acetylphenoxy)-N-[[4-(1-hydroxyethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214757-15-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-acetylphenoxy)-N-[[4-(aminosulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214757-17-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[(2-chlorophenyl)methyl]-2-[3-(1-hydroxy-1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 214757-18-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[3-(1-hydroxy-1-methylethyl)phenoxy]-N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214757-19-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]-2-[3-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 214757-21-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-(2,4-difluorophenoxy)-N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214757-22-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3,4-difluorophenoxy)-N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214757-23-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3,4-difluorophenoxy)-N-[[4-(1-hydroxycyclobutyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214757-24-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[[2-chloro-4-(1-hydroxy-1-methylethyl)phenyl]methyl]-2-(3,4-difluorophenoxy)- (9CI) (CA INDEX NAME)



RN 214757-26-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-acetylphenoxy)-N-[[2-chloro-4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214757-27-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-acetylphenoxy)-N-[[2-chloro-4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214757-28-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-acetylphenoxy)-N-[[2-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214757-29-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3,5-difluorophenoxy)-N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214757-34-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-cyano-4-fluorophenoxy)-N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214757-35-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[[2-chloro-4-(1-hydroxy-1-methylethyl)phenyl]methyl]-2-(3-cyano-4-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 214757-38-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(dimethylamino)phenyl]methyl]-2-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 214757-40-1 CAPLUS
CN 1-Propanone, 1-[2-(4-fluorophenoxy)-3-pyridinyl]-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 214757-41-2 CAPLUS
CN 1-Propanone, 3-(2-chlorophenyl)-1-[2-(4-fluorophenoxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 214757-42-3 CAPLUS
CN 1-Propanone, 1-[2-(4-fluorophenoxy)-3-pyridinyl]-3-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 214757-43-4 CAPLUS
CN 1-Propanone, 1-[2-(4-fluorophenoxy)-3-pyridinyl]-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 214757-44-5 CAPLUS
CN 1-Propanone, 1-[2-(4-fluorophenoxy)-3-pyridinyl]-3-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 214757-45-6 CAPLUS
CN 1-Propanone, 3-(3,5-difluorophenyl)-1-[2-(4-fluorophenoxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 214757-46-7 CAPLUS
CN 1-Propanone, 1-[2-(4-fluorophenoxy)-3-pyridinyl]-3-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 214757-47-8 CAPLUS
CN 1-Propanone, 1-[2-(4-fluorophenoxy)-3-pyridinyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 214757-50-3 CAPLUS
CN 1-Propanone, 1-[2-(4-fluorophenoxy)-3-pyridinyl]-2-methyl-3-phenyl- (9CI) (CA INDEX NAME)



RN 214757-52-5 CAPLUS
CN 1-Butanone, 1-[2-(4-fluorophenoxy)-3-pyridinyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 214757-55-8 CAPLUS
CN Ethanone, 1-[2-(4-fluorophenoxy)-3-pyridinyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 214757-58-1 CAPLUS
CN 2-Propen-1-one, 1-[2-(4-fluorophenoxy)-3-pyridinyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 214757-62-7 CAPLUS
CN 1-Propanone, 1-[2-(4-fluorophenoxy)-3-pyridinyl]-3-hydroxy-3-phenyl- (9CI) (CA INDEX NAME)



RN 214757-68-3 CAPLUS
CN 2-Propen-1-one, 1-[2-(4-fluorophenoxy)-3-pyridinyl]-3-(4-methoxyphenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 214757-69-4 CAPLUS
CN 2-Propen-1-one, 1-[2-(4-fluorophenoxy)-3-pyridinyl]-3-phenyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 214757-70-7 CAPLUS

CN 1-Propanone, 1-[2-(4-fluorophenoxy)-3-pyridinyl]-2,3-dihydroxy-3-(4-methoxyphenyl)-, (2R,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 214757-71-8 CAPLUS
CN 1-Propanone, 1-[2-(4-fluorophenoxy)-3-pyridinyl]-2,3-dihydroxy-3-phenyl-, (2R,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 214757-74-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[(2-chlorophenyl)methyl]-2-(3-methoxyphenoxy)- (9CI) (CA INDEX NAME)



RN 214757-75-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(2,3-dihydro-1-oxo-1H-inden-4-yl)oxy]-N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214757-76-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[(4-acetylphenyl)methyl]-2-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 214757-78-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[[4-(1-hydroxyethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214757-80-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[3-(aminocarbonyl)phenoxy]-N-[(2-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 214757-81-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[3-[(dimethylamino)carbonyl]phenoxy]-N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214757-82-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]-2-[3-(trifluoroacetyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 214757-83-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]-2-[3-(2,2,2-trifluoro-1-hydroxyethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 214757-84-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214757-85-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[3-(aminocarbonyl)phenoxy]-N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214757-88-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(2,3-dihydro-3-oxo-1H-inden-5-yl)oxy]-N-[[4-(1-

hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214757-89-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]-2-[(2-methyl-5-benzothiazolyl)oxy]- (9CI) (CA INDEX NAME)



RN 214757-90-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]-2-[(2-methyl-6-benzothiazolyl)oxy]- (9CI) (CA INDEX NAME)



RN 214757-91-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-(6-benzothiazolyloxy)-N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214757-92-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-(6-benzoxazolyloxy)-N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214757-93-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-acetyl-4-chlorophenoxy)-N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214757-94-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]-2-[(3-methyl-1,2-benzisoxazol-7-yl)oxy]- (9CI) (CA INDEX NAME)



RN 214757-95-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-acetyl-5-chlorophenoxy)-N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214757-96-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-acetylphenoxy)-N-[[4-[(1S)-1-hydroxyethyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 214757-97-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-acetylphenoxy)-N-[[4-[(1R)-1-hydroxyethyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 214758-00-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-acetyl-5-chlorophenoxy)-N-[[2-chloro-4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214758-01-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-acetyl-4-chlorophenoxy)-N-[[2-chloro-4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214758-03-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]-2-[(3-methyl-1,2-benzisoxazol-5-yl)oxy]- (9CI) (CA INDEX NAME)



RN 214758-10-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(2,3-dihydro-1,4-benzodioxin-6-yl)oxy]-N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214758-14-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-(1,3-benzodioxol-5-yloxy)-N-[[2-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214758-15-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[[2-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]methyl]-2-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 214758-17-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[3-[1-(hydroxyimino)ethyl]phenoxy]-N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214758-18-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(3,4-dihydro-4-oxo-2H-1-benzopyran-6-yl)oxy]-N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214758-20-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[[4-(1-hydroxy-1-methylethyl)phenyl]methyl]-2-[3-[1-(methoxyimino)ethyl]phenoxy]- (9CI) (CA INDEX NAME)



IT **214759-82-7P 214759-83-8P 214759-84-9P**
214759-86-1P 214759-87-2P 214759-88-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of nicotinamides as PDE4 D isoenzymes inhibitors)

RN 214759-82-7 CAPLUS
CN 3-Pyridinepropanoic acid, .alpha.-[(2-chlorophenyl)methyl]-2-(4-fluorophenoxy)-.beta.-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 214759-83-8 CAPLUS
CN 3-Pyridinepropanoic acid, 2-(4-fluorophenoxy)-.alpha.-[(4-fluorophenyl)methyl]-.beta.-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 214759-84-9 CAPLUS
CN 3-Pyridinepropanoic acid, 2-(4-fluorophenoxy)-.beta.-oxo-.alpha.-[[4-(trifluoromethyl)phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 214759-86-1 CAPLUS
CN 3-Pyridinepropanoic acid, 2-(4-fluorophenoxy)-.beta.-oxo-.alpha.-[[4-(trifluoromethoxy)phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 214759-87-2 CAPLUS
CN 3-Pyridinepropanoic acid, .alpha.-[(3,5-difluorophenyl)methyl]-2-(4-fluorophenoxy)-.beta.-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 214759-88-3 CAPLUS
CN 3-Pyridinepropanoic acid, 2-(4-fluorophenoxy)-.beta.-oxo-.alpha.-[(2,4,6-

trifluorophenyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:543220 CAPLUS
DOCUMENT NUMBER: 129:175563
TITLE: 4-Substituted quinoline derivatives and 4-substituted quinoline combinatorial libraries
INVENTOR(S): Hayes, Thomas K.; Forood, Behrouz; Kiely, John S.
PATENT ASSIGNEE(S): Trega Biosciences, Inc., USA
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9834115	A1	19980806	WO 1997-US22391	19971205
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9881919	A1	19980825	AU 1998-81919	19971205
EP 977989	A1	20000209	EP 1997-949775	19971205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6262269	B1	20010717	US 1998-17785	19980203
US 6388081	B1	20020514	US 1999-376670	19990816

PRIORITY APPLN. INFO.: US 1997-795392 A 19970204
US 1997-126414P P 19970204
WO 1997-US22391 W 19971205
US 1998-17785 A3 19980203

OTHER SOURCE(S): MARPAT 129:175563
GI



I



II

AB The invention relates to novel 4-substituted quinoline derivs. I, their salts, and combinatorial libraries contg. mixts. of two or more such compds. [wherein R1 = bond, (un)substituted alk(en/yn)ylene, cycloalk(en)ylene, phenylene, naphthylene, heterocycle, heteroaryl, amino, CH2CONH, (CH2)pAr(CH2)q, etc.; p, q = 0-6 but both cannot be 0; Ar = (un)substituted Ph or heteroaryl; R2, R3, R4 = H, halo, (un)protected OH, cyano, NO2, (un)substituted alk(en/yn)yl, alkoxy, cycloalk(en)yl, heterocyclyl, phenylalkyl, Ph, naphthyl, etc.; R5 = H, (un)substituted alk(en/yn)yl, cycloalk(en)yl, Ph, naphthyl, phenylalkyl, (un)protected CO2H, acyl, heterocyclyl, etc.; R6 = H, (un)substituted Ph, naphthyl, 2-oxopyrrolidin-1-yl and higher homologs, (un)substituted NHCHO; R7 = H, (un)substituted alkyl; Y = CO2H, OH, SH, NHR8, CONHR8, CH2OH, CH2NH2, CH2NHR8; R8 = H, (un)substituted alkyl, or functionalized resin; R9 = H, (un)substituted alkyl, phenylalkyl, acyl, PhSO2, alkylsulfonyl, alkylaminocarbonyl, or PhNHCO, or is absent; dotted lines = optional pi bonds]. The invention also relates to the generation of such libraries. In 12 examples, libraries of I ranging in size from 2380 to 39,440 compds. were prepd. as mixed sublibraries. Data for control compds. (samples of individually known intermediates and products, cleaved from simultaneously processed control resins) are given for some examples. Both quinoline and tetrahydroquinoline libraries were prepd. For instance, tea-bags of MBHA resin were each coupled with L- or D-N-BOC-p-nitrophenylalanine, the BOC groups were removed from both, and the amino groups were each acylated with 170 carboxylic acids. The acylated, resin-bound products were mixed and reduced at the nitro group, and the amine product mixts. were condensed with 58 different aldehydes and cyclized with 4-methoxystyrene. Cleavage of the resin-bound products with HF gave mixed sublibraries of I. Individual control samples of products, such as II [R5 = 1-naphthyl, 2,3-difluorophenyl, cyclohexyl, etc.], were obtained by reactions of pure, resin-bound L-N-propanoyl-p-aminophenylalanine control samples with individual aldehydes and 4-methoxystyrene. Potential applications of I (no data) may include use as antibacterials, NMDA antagonists, or analgesics.

IT **211375-85-8P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(resin-cleavage control intermediate; prepn. of tricyclic tetrahydroquinoline derivs. and combinatorial libraries)

RN 211375-85-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-amino-1-[(4-nitrophenyl)methyl]-2-oxoethyl]-2-[[3-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:543216 CAPLUS
DOCUMENT NUMBER: 129:175562
TITLE: Tricyclic tetrahydroquinoline derivatives and tricyclic tetrahydroquinoline combinatorial libraries
INVENTOR(S): Hayes, Thomas K.; Kiely, John S.
PATENT ASSIGNEE(S): Trega Biosciences, Inc., USA
SOURCE: PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9834111	A1	19980806	WO 1997-US22206	19971205
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5925527	A	19990720	US 1997-795893	19970204
AU 9855928	A1	19980825	AU 1998-55928	19971205
NZ 337046	A	20000128	NZ 1997-337046	19971205
EP 983507	A1	20000308	EP 1997-952280	19971205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: US 1997-795893 A 19970204
WO 1997-US22206 W 19971205
OTHER SOURCE(S): MARPAT 129:175562
GI



I



II

AB The invention relates to novel tricyclic tetrahydroquinoline compds. I, their salts, and combinatorial libraries contg. mixts. of two or more such compds. [wherein R1 = bond, (un)substituted alk(en/yn)ylene, cycloalk(en)ylene, phenylene, naphthylene, heterocycle, heteroaryl, amino, CH2CONH, (CH2)pAr(CH2)q; p, q = 0-6 but both cannot be 0; Ar = (un)substituted Ph or heteroaryl; R2, R3, R4 = H, halo, (un)protected OH, cyano, NO2, (un)substituted alk(en/yn)yl, alkoxy, cycloalk(en)yl, heterocyclyl, phenylalkyl, Ph, naphthyl, etc.; R5 = H, (un)substituted alk(en/yn)yl, cycloalk(en)yl, Ph, naphthyl, phenylalkyl, (un)protected CO2H, acyl, heterocyclyl, etc.; R6 = H, (un)substituted alkyl, phenylalkyl, acyl, PhSO2, alkylsulfonyl, alkylaminocarbonyl, PhNHCO; n = 1-3; Y = CO2H, OH, SH, NHR7, CONHR7, CH2OH, CH2NH2, CH2NHR7; R7 = H, (un)substituted alkyl, or functionalized resin; R1 must be present and R5 .noteq. Ph when Y = CO2H]. The invention also relates to the generation of such libraries. In 2 examples, libraries of 2774 and approx. 17,000 compds. I were prepd. as mixed sublibraries. Data for control compds. (samples of individually known intermediates and products, cleaved from simultaneously processed control resins) are given. For instance, tea-bags of MBHA resin were each coupled with one of 19 aminobenzoic acids, such as 4-aminobenzoic acid. Diagnostic cleavage of each of these resins with HF gave 19 aminobenzamide controls in 34-99% yield. The 19 resins were mixed together and placed in new tea-bags, then condensed with 73 different aldehydes, and finally cyclized with cyclopentadiene. Cleavage of the resin-bound products with HF gave approx. 73 mixts. of 38 compds. (counting sep. enantiomers). Individual control samples of products, such as II [R5 = H, CH2Cl, cyclohexyl, CO2H, (un)substituted Ph, etc.], were typically obtained in 50-100% yield by reactions of pure, resin-bound 4-aminobenzoic acid control samples in sibling tea-bags. Potential applications of I (no data) may include use as antibacterials or analgesics.

IT **211375-85-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(resin-cleavage control intermediate; prepn. of tricyclic tetrahydroquinoline derivs. and combinatorial libraries)

RN 211375-85-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-amino-1-[(4-nitrophenyl)methyl]-2-oxoethyl]-2-[[3-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:557640 CAPLUS
DOCUMENT NUMBER: 127:248103
TITLE: Substituted biphenyl isoxazole sulfonamides useful as endothelin antagonists
INVENTOR(S): Murugesan, Natesan; Barrish, Joel C.; Spergel, Steven H.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 325 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9729748	A1	19970821	WO 1997-US3956	19970220
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5846990	A	19981208	US 1997-799616	19970213
ZA 9701423	A	19980819	ZA 1997-1423	19970219
AU 9722098	A1	19970902	AU 1997-22098	19970220
AU 720458	B2	20000601		
EP 921800	A1	19990616	EP 1997-915055	19970220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002500619	T2	20020108	JP 1997-529620	19970220

PRIORITY APPLN. INFO.:
US 1996-603975 A 19960220
US 1996-754715 A 19961121
US 1997-799616 A 19970213
US 1995-493331 B2 19950724
WO 1997-US3956 W 19970220

OTHER SOURCE(S): MARPAT 127:248103
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I inhibit the activity of endothelin (no data), and are useful as antihypertensives, etc. The symbols in I are defined as follows [one of X and Y = N, other = O; J = O, S, N, (un)substituted NH; K, L = N or C, provided that at least one is C; p = 0-2; R1-R4 (bound to ring C atoms) = H, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl, aralkoxy, halo, OH, cyano, NO2, CHO, etc.; or R3R4 = (un)substituted alkylene or alkenylene; R5-R8 = groups similar to R1-R4, plus heterocyclyl, heterocyclyloxy, and others]. Over 280 synthetic examples are given. For instance, the MEM-protected, isoxazole-contg. bromide II [R = Br] was lithiated, treated with B(OPr-iso)3, and hydrolyzed to give 82% II [R = B(OH)2]. The latter was coupled with 2-(4-bromophenyl)oxazole

using Pd(PPh3)4 catalyst (70%), followed by acidic deprotection of the MEM group (52%), to give title compd. III.

IT **195446-37-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted biphenyl isoxazole sulfonamides as endothelin antagonists)

RN 195446-37-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[[2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N-methyl-2-phenoxy- (9CI) (CA INDEX NAME)



L4 ANSWER 19 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1994:217217 CAPLUS
DOCUMENT NUMBER: 120:217217
TITLE: Alkylamides of 2-chloro- and 2-arylamino-4,6-dimethylnicotinic acid: synthesis and anticonvulsant activity
AUTHOR(S): Demina, L. M.; Danilova, V. K.; Drovosekova, L. P.; Kolla, V. P.; Konshin, M. E.
CORPORATE SOURCE: Perm. Farm. Inst., Russia
SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1993), 27(7), 34-5
CODEN: KHFZAN; ISSN: 0023-1134
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI



AB Amination of nicotinamides I (R = H, R1 = alkyl, cycloalkyl, PhCH2; NRR1 = piperidino, morpholino), prepd. in 35-66% yields from the corresponding nicotinoyl chloride and RNH2, by 4-R2C6H4NH2.HCl (R2 = H, OMe) gave 30-67% anilinoamides II.HCl. Tests on white mice confirmed that the substituted amides were less active than their unsubstituted derivs.

IT **153878-09-2P 153878-10-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 153878-09-2 CAPLUS
CN 3-Pyridinecarboxamide, 4,6-dimethyl-2-(phenylamino)-N-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 153878-10-5 CAPLUS
CN 3-Pyridinecarboxamide, 4,6-dimethyl-2-(phenylamino)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 20 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1994:164213 CAPLUS
DOCUMENT NUMBER: 120:164213
TITLE: Pyrido[2,3-d]pyrimidinone phosphodiesterase inhibitors
INVENTOR(S): Wilhelm, Robert Stephen; Chin, Ronnie Lipp; Devens, Bruce Henry; Alvarez, Robert
PATENT ASSIGNEE(S): Syntex (U.S.A.), Inc., USA
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9319068	A1	19930930	WO 1993-US2273	19930318
W: AU, CA, FI, HU, JP, KR, NO, NZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5264437	A	19931123	US 1992-855179	19920320
AU 9339186	A1	19931021	AU 1993-39186	19930318
AU 669520	B2	19960613		
ZA 9301945	A	19940918	ZA 1993-1945	19930318
EP 631580	A1	19950104	EP 1993-908322	19930318
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
HU 67552	A2	19950428	HU 1994-2653	19930318
JP 07504676	T2	19950525	JP 1993-516634	19930318

JP 3241384	B2	20011225			
IL 105092	A1	19980615	IL 1993-105092		19930318
CN 1040327	B	19981021	CN 1993-103352		19930318
FI 9404305	A	19940916	FI 1994-4305		19940916
NO 9403456	A	19940916	NO 1994-3456		19940916
PRIORITY APPLN. INFO.:			US 1992-855179	A	19920320
			WO 1993-US2273	A	19930318

OTHER SOURCE(S): MARPAT 120:164213
GI



I

AB The title compds. I [R1 = H, (CH2)nR7; R7 = aryl, heteroaryl; n = 1, 2; R2-R6 = H, lower alkyl, halogen, CO2H, CO2Me, carbamoyl, etc.; Y = CH2, CO; only one of R2-R6 may be other than H], useful for the treatment of asthma, pain, inflammatory diseases, etc., are prepd. and I-contg. formulations presented. Thus, I (R1= 3-pyridylmethyl, R2 = R4 = R6 = H, R3 = NO2, Y = CO) was prepd. and demonstrated 50% inhibitory concn. for human lymphocyte cAMP phosphodiesterase (PDE 4) of 0.00026 .mu.M.

IT **152814-88-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, in prepn. of phosphodiesterase inhibitors)

RN 152814-88-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(3-acetylphenyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 21 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1993:560137 CAPLUS
DOCUMENT NUMBER: 119:160137
TITLE: Herbicidal and plant-nematocidal compositions based on mercaptonicotinic acid derivatives
INVENTOR(S): Jeschke, Peter; Lindner, Werner; Bonse, Gerhard; Santel, Hans Joachim; Luerssen, Klaus; Schmidt, Robert R.; Hartwig, Juergen
PATENT ASSIGNEE(S): Bayer A.-G., Germany

SOURCE: Eur. Pat. Appl., 25 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 550900	A1	19930714	EP 1992-122055	19921228
R: BE, CH, DE, FR, GB, IT, LI, NL				
DE 4200323	A1	19930715	DE 1992-4200323	19920109
JP 05271010	A2	19931019	JP 1993-15839	19930106

PRIORITY APPLN. INFO.: DE 1992-4200323 19920109
OTHER SOURCE(S): MARPAT 119:160137
GI



I



II

AB The title compds., N-(benzyl)-2-mercaptonicotinamides I (R1 = hydrogen, halo, alkyl, etc.; R2 = alkyl, alkenyl, etc.; R3 = halo, cyano, nitro, etc.; R4 = alkyl) and their uses as herbicides and nematocides are claimed. Condensation of 2-(methylthio)nicotinoyl chloride with (.+-.)-1-(4-methylphenl)ethylamine gave (.+-.)-N-[1-(4-methylphenyl)ethyl]-2-(methylthio)nicotinamide (II).

IT **150062-93-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as herbicide or nematocide or anthelmintic)

RN 150062-93-4 CAPLUS

CN 3-Pyridinecarboxamide, N-(1-phenylethyl)-2-(phenylthio)- (9CI) (CA INDEX NAME)



L4 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1993:183433 CAPLUS
DOCUMENT NUMBER: 118:183433
TITLE: Pyridine derivatives as accelerators of nerve growth factor production

INVENTOR(S): Ono, Takashi; Kishimoto, Toshimitsu; Nakajima, Toru; Ono, Yuji
PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd., Japan; Japan Tobacco, Inc.
SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04352721	A2	19921207	JP 1991-112392	19910417
PRIORITY APPLN. INFO.:			JP 1990-112381	19900426

OTHER SOURCE(S): MARPAT 118:183433
GI



I

AB The pyridine derivs. are I where R1 and R2 = H, alkyl; Ar = (un)substituted Ph, pyridyl, thienyl, etc.; Y = alkylene that may contain single or double bonds; W = phenoxy analog groups. These compds. showed a remarkable nerve growth factor prodn. in a culture medium contg. mouse astroglial cells. The compds. are useful in controlling central nervous system.

IT **129182-62-3 129182-98-5 129183-01-3**
129183-03-5 129183-06-8 129183-07-9
129183-09-1 146795-07-5 146842-24-2
RL: BIOL (Biological study)
(nerve growth factor formation enhancement by, in astroglial cells)

RN 129182-62-3 CAPLUS
CN 2-Propen-1-one, 1-[2-[4,5-dichloro-2-[2-(dimethylamino)ethoxy]phenoxy]-3-pyridinyl]-3-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 129182-98-5 CAPLUS
CN 1-Propanone, 1-[2-[4,5-dichloro-2-[2-(dimethylamino)ethoxy]phenoxy]-3-

pyridinyl]-3-phenyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 129182-97-4
CMF C24 H24 Cl2 N2 O3



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 129183-01-3 CAPLUS
CN 2-Propen-1-one, 3-(4-chlorophenyl)-1-[2-[4,5-dichloro-2-[2-(diethylamino)ethoxy]phenoxy]-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 129183-03-5 CAPLUS
CN 2-Propen-1-one, 3-(4-chlorophenyl)-1-[2-[4,5-dichloro-2-[3-(dimethylamino)propoxy]phenoxy]-3-pyridinyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 129183-02-4

CMF C25 H23 Cl3 N2 O3



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 129183-06-8 CAPLUS
CN 2-Propen-1-one, 1-[2-[4,5-dichloro-2-[2-(dimethylamino)ethoxy]phenoxy]-3-pyridinyl]-3-(4-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 129183-07-9 CAPLUS
CN 2-Propen-1-one, 3-(2-chlorophenyl)-1-[2-[4,5-dichloro-2-[2-(dimethylamino)ethoxy]phenoxy]-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 129183-09-1 CAPLUS
CN 2-Propen-1-one, 1-[2-[2-[2-(dimethylamino)ethoxy]phenoxy]-3-pyridinyl]-3-phenyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 129183-08-0
CMF C24 H24 N2 O3



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown..



RN 146795-07-5 CAPLUS
CN 2-Propen-1-one, 1-[2-[4,5-dichloro-2-[2-[4-(dimethylamino)-1-piperidinyl]ethoxy]phenoxy]-6-(1-methylethyl)-3-pyridinyl]-3-phenyl-, (2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 146795-06-4
CMF C32 H37 Cl2 N3 O3



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 146842-24-2 CAPLUS
CN 2-Propen-1-one, 1-[2-[4,5-dichloro-2-[2-(dimethylamino)ethoxy]phenoxy]-6-(1-methylethyl)-3-pyridinyl]-3-phenyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 146842-23-1
CMF C27 H28 Cl2 N2 O3



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L4 ANSWER 23 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1991:679818 CAPLUS
DOCUMENT NUMBER: 115:279818
TITLE: Preparation of piperidine derivatives as neurokinin and substance P antagonists
INVENTOR(S): Emonds-Alt, Xavier; Goulaouic, Pierre; Proietto, Vincenzo; Van Broeck, Didier
PATENT ASSIGNEE(S): SANOFI, Fr.
SOURCE: Eur. Pat. Appl., 84 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 428434	A2	19910522	EP 1990-403125	19901106
EP 428434	A3	19911009		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FR 2654100	A1	19910510	FR 1989-14517	19891106
FR 2654100	B1	19920221		
FR 2663329	A1	19911220	FR 1990-7534	19900615
FR 2663329	B1	19921016		
FI 97540	B	19960930	FI 1990-5444	19901102
FI 97540	C	19970110		
CA 2029275	AA	19910507	CA 1990-2029275	19901105
NO 9004802	A	19910507	NO 1990-4802	19901105
NO 177299	B	19950515		
NO 177299	C	19950823		
AU 9065838	A1	19910523	AU 1990-65838	19901105
AU 649973	B2	19940609		
HU 56543	A2	19910930	HU 1990-7027	19901105
US 5317020	A	19940531	US 1990-610093	19901105
IL 111292	A1	19960331	IL 1990-111292	19901105
RU 2084453	C1	19970720	RU 1990-4831627	19901105
RU 2114828	C1	19980710	RU 1993-45020	19901105
ZA 9008881	A	19910828	ZA 1990-8881	19901106
JP 03206086	A2	19910909	JP 1990-300929	19901106
PL 165758	B1	19950228	PL 1990-293823	19901106
PL 165854	B1	19950228	PL 1990-293824	19901106
PL 166565	B1	19950630	PL 1990-287644	19901106
PL 166582	B1	19950630	PL 1990-303827	19901106
IL 96241	A1	19960331	IL 1990-96241	19901115
LV 10713	B	19951020	LV 1993-142	19930225
US 5686609	A	19971111	US 1994-208672	19940311
AU 9459245	A1	19940602	AU 1994-59245	19940331
AU 668018	B2	19960418		
NO 9500239	A	19910507	NO 1995-239	19950123
NO 180193	B	19961125		
NO 180193	C	19970305		
NO 9500240	A	19910507	NO 1995-240	19950123
NO 179580	B	19960729		
NO 179580	C	19961106		
US 5618938	A	19970408	US 1995-479634	19950607
FI 9502956	A	19950615	FI 1995-2956	19950615
FI 9502957	A	19950615	FI 1995-2957	19950615
FI 9800227	A	19980202	FI 1998-227	19980202

PRIORITY APPLN. INFO.:

FR 1989-14517	A	19891106
FR 1990-7534	A	19900615
FI 1990-5444	A	19901102
NO 1990-4802	A	19901105

US 1990-610093 A3 19901105
IL 1990-96241 A3 19901115
US 1994-208672 A3 19940311
FI 1995-2956 A 19950615

OTHER SOURCE(S): MARPAT 115:279818

GI



I



II

AB The title compds. I [m = 1-3; Ar, Ar' = thienyl, (substituted) Ph, etc.; X = H; X' = H, OH; or XX' = oxo, dialkylaminoalkyloxyimino, etc.; Y = N, CX''; X'' = H or X'X'' = carbon-carbon bond; Q = H, alkyl, (CH2)qAm'; q = 2 or 3; Am' = piperidino, 4-benzylpiperidino, etc.; R = H, Me, (CH2)nL; n = 2-6; L = H, amino; T = CO, C(W)NH; W = O, S; Z = H, M, or OM when T = CO; or Z = M when T = C(W)NH; M = H, alkyl, (substituted) phenylalkyl, etc.] were prepd. I are neurokinin and substance P antagonists (no data). Reaction of amine II (Z1 = H) with 2,4-dichlorobenzoyl chloride in the presence of Et3N gave II (Z1 = 2,4-dichlorobenzoyl) isolated as its HCl salt. I are also useful as allergy and inflammation inhibitors (no data).

IT **135956-47-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as neurokinin antagonist)

RN 135956-47-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-(3,4-dichlorophenyl)-4-[4-(phenylmethyl)-1-piperidinyl]butyl]-2-[(3,5-dimethoxyphenyl)thio]-, dihydrochloride (9CI) (CA INDEX NAME)



L4 ANSWER 24 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1991:61890 CAPLUS
DOCUMENT NUMBER: 114:61890
TITLE: Nicotinamide ethers: novel inhibitors of calcium-independent phosphodiesterase and [3H]rolipram binding
AUTHOR(S): Vinick, Fredric J.; Saccomano, Nicholas A.; Koe, B. Kenneth; Nielsen, Jann A.; Williams, Ian H.; Thadeio, Peter F.; Jung, Stanley; Meltz, Morgan; Johnson, Jonathan, Jr.; et al.
CORPORATE SOURCE: Pfizer Cent. Res., Groton, CT, 06340, USA
SOURCE: Journal of Medicinal Chemistry (1991), 34(1), 86-9
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 114:61890
GI



I

AB The synthesis and biol. properties of a series of nicotinamide ethers I (R = Ph, substituted Ph, bicycloheptyl; R1 = Ph, CH2Ph, CH2C6H4R2-4; R2 = F, Me, OMe) are described. I are structurally novel calcium-independent phosphodiesterase inhibitors and they also inhibit the binding of [3H]rolipram to rat brain membranes and reverse reserpine-induced hypothermia in the mouse. Several compds. exhibited potent in vivo activity comparable to the std. agent, rolipram.

IT **125038-37-1P 125038-39-3P 125038-40-6P**
125038-41-7P 125038-42-8P 125038-43-9P
125038-44-0P 125038-46-2P 125038-52-0P
125038-53-1P 125038-56-4P 131236-85-6P
131236-86-7P 131236-87-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and calcium-independent phosphodiesterase and rolipram binding

inhibitory activity of)

RN 125038-37-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-fluorophenoxy)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 125038-39-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-cyanophenoxy)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 125038-40-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-methoxyphenoxy)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 125038-41-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(phenylmethyl)-2-[3-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 125038-42-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3,4-dichlorophenoxy)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 125038-43-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)





RN 125038-44-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-phenoxy-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 125038-46-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 125038-52-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)





RN 125038-53-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 125038-56-4 CAPLUS
CN Benzoic acid, 3-[[3-[[(phenylmethyl)amino]carbonyl]-2-pyridinyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 131236-85-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-methoxyphenoxy)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 131236-86-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-(2-fluorophenoxy)-N-(phenylmethyl)- (9CI) (CA

INDEX NAME)



RN 131236-87-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-(2-methoxyphenoxy)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 25 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1990:515095 CAPLUS
DOCUMENT NUMBER: 113:115095
TITLE: Preparation of 2-alkylthio-3-(2-thenoyl)pyridines and analogs as proline endopeptidase inhibitors
INVENTOR(S): Oe, Takanori; Ono, Yuji; Kawasaki, Kazuyuki; Nakajima, Tohru
PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd., Japan
SOURCE: Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 359547	A1	19900321	EP 1989-309297	19890913
EP 359547	B1	19960124		
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
JP 02275858	A2	19901109	JP 1989-236639	19890912
JP 2531989	B2	19960904		
EP 558094	A1	19930901	EP 1993-103799	19890913
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
AT 133410	E	19960215	AT 1989-309297	19890913
US 5001137	A	19910319	US 1989-407010	19890914
PRIORITY APPLN. INFO.:			JP 1988-231261	19880914
			JP 1989-8971	19890117

OTHER SOURCE(S): MARPAT 113:115095
GI



I



Q



II

AB The title compds. [I; R1, R2 = H, halo, alkyl, alkoxy, (un)substituted Ph; Ar = (un)substituted (hetero)aryl; Y = bond, alk(en)ylene; W = aryl radical Q; R3, R4 = any of definitions for R1, R2; X = O, S, NR5; R5 = H, alkyl, acyl; Z = bond, O, S, NR6; R6 = R5, CONR5; A = alkylene; B = OH, CO2H, alkoxycarbonyl, etc.] or their salts, useful for the prophylaxis and treatment of amnesia, were prepd. A soln. of 4-[2-(dimethylamino)ethyl]phenol in DMF was added dropwise to NaH in DMF, the mixt. was stirred 2 h at 60.degree., 2-chloro-3-(2-thenoyl)pyridine in DMF was added dropwise under ice-cooling, and the whole was stirred 2 h at 70.degree. to give the title compd. II, which was converted to its semifumarate salt. II (form unspecified) in vitro inhibited proline endopeptidase with IC50 of 0.014 .mu.M. A tablet was formulated contg. II.

IT **129182-49-6P 129182-50-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, in prepn. of proline endopeptidase inhibitor)

RN 129182-49-6 CAPLUS

CN 2-Propen-1-one, 1-[2-(4,5-dichloro-2-methoxyphenoxy)-3-pyridinyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 129182-50-9 CAPLUS

CN 2-Propen-1-one, 1-[2-(4,5-dichloro-2-hydroxyphenoxy)-3-pyridinyl]-3-phenyl- (9CI) (CA INDEX NAME)



IT **129182-61-2P 129182-62-3P 129182-98-5P**
129183-00-2P 129183-01-3P 129183-03-5P
129183-05-7P 129183-06-8P 129183-07-9P
129183-09-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as proline endopeptidase inhibitor)
RN 129182-61-2 CAPLUS
CN 2-Propen-1-one, 1-[2-[4,5-dichloro-2-[2-(dimethylamino)ethoxy]phenoxy]-3-pyridinyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 129182-62-3 CAPLUS
CN 2-Propen-1-one, 1-[2-[4,5-dichloro-2-[2-(dimethylamino)ethoxy]phenoxy]-3-pyridinyl]-3-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 129182-98-5 CAPLUS
CN 1-Propanone, 1-[2-[4,5-dichloro-2-[2-(dimethylamino)ethoxy]phenoxy]-3-pyridinyl]-3-phenyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 129182-97-4
CMF C24 H24 Cl2 N2 O3



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 129183-00-2 CAPLUS
CN 1-Propanone, 3-(4-chlorophenyl)-1-[2-[4,5-dichloro-2-[3-(dimethylamino)propoxy]phenoxy]-3-pyridinyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 129182-99-6
CMF C25 H25 Cl3 N2 O3



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 129183-01-3 CAPLUS
CN 2-Propen-1-one, 3-(4-chlorophenyl)-1-[2-[4,5-dichloro-2-[2-

(diethylamino)ethoxy]phenoxy]-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 129183-03-5 CAPLUS
CN 2-Propen-1-one, 3-(4-chlorophenyl)-1-[2-[4,5-dichloro-2-[3-(dimethylamino)propoxy]phenoxy]-3-pyridinyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 129183-02-4
CMF C25 H23 Cl3 N2 O3



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 129183-05-7 CAPLUS
CN 2-Propen-1-one, 1-[2-[4,5-dichloro-2-[2-(dimethylamino)ethoxy]phenoxy]-3-pyridinyl]-3-(3-nitrophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 129183-06-8 CAPLUS
CN 2-Propen-1-one, 1-[2-[4,5-dichloro-2-[2-(dimethylamino)ethoxy]phenoxy]-3-pyridinyl]-3-(4-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 129183-07-9 CAPLUS
CN 2-Propen-1-one, 3-(2-chlorophenyl)-1-[2-[4,5-dichloro-2-[2-(dimethylamino)ethoxy]phenoxy]-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 129183-09-1 CAPLUS
CN 2-Propen-1-one, 1-[2-[2-[2-(dimethylamino)ethoxy]phenoxy]-3-pyridinyl]-3-phenyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 129183-08-0
CMF C24 H24 N2 O3



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L4 ANSWER 26 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1990:76962 CAPLUS
DOCUMENT NUMBER: 112:76962
TITLE: Preparation of antidepressant N-substituted nicotinamides
INVENTOR(S): Saccomano, Nicholas A.; Vinick, Frederic J.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 10 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4861891	A	19890829	US 1988-238951	19880831
EP 357316	A1	19900307	EP 1989-308481	19890822
EP 357316	B1	19930414		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 88182	E	19930415	AT 1989-308481	19890822
CA 1329605	A1	19940517	CA 1989-609655	19890829
DK 8904268	A	19900301	DK 1989-4268	19890830
FI 8904066	A	19900301	FI 1989-4066	19890830
NO 8903471	A	19900301	NO 1989-3471	19890830
JP 02115168	A2	19900427	JP 1989-224342	19890830
AU 8940913	A1	19900628	AU 1989-40913	19890830
AU 609329	B2	19910426		
HU 52058	A2	19900628	HU 1989-4507	19890830
HU 208120	B	19930830		
ZA 8906626	A	19910424	ZA 1989-6626	19890830

PRIORITY APPLN. INFO.: US 1988-238951 19880831

EP 1989-308481 19890822
OTHER SOURCE(S): CASREACT 112:76962; MARPAT 112:76962

GI



I

AB The title compds. [I; R1 = 1-piperidyl, 1-(3-indolyl)ethyl, C1-4 alkyl, Ph, PhCH2CH2, (monosubstituted) PhCH2; R2 = bicyclo[2.2.1]hept-2-yl, phenyl group Q; R3 = H, F, Cl, MeO, CF3, CN, CO2H, MeNHCO, Me2NCO, C1-4 carboalkoxy; R4 = H, F, Cl], useful as CNS agents, particularly antidepressants (no data), were prepd. Thus, 2-(4-fluorophenoxy)nicotinic acid (prepn. from 3-FC6H4OH and 2-chloronicotinic acid given) in THF at -5.degree. was treated with N-methylmorpholine and Me2CHCH2OCOCl followed, after 1 h, with tryptamine. The mixt. was stirred 18 h at room temp. to give 52.4% N-[2-(3-indolyl)ethyl]-2-(4-fluorophenoxy)nicotinamide. I are selective inhibitors of Ca-independent c-AMP phosphodiesterase which exhibit biochem. and behavioral profiles similar to those of rolipran with increased duration of action.

IT **125038-37-1P 125038-39-3P 125038-40-6P**
125038-41-7P 125038-42-8P 125038-43-9P
125038-44-0P 125038-46-2P 125038-47-3P
125038-49-5P 125038-52-0P 125038-53-1P
125038-54-2P 125038-55-3P 125038-56-4P
125038-63-3P 125057-86-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as antidepressant)

RN 125038-37-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-fluorophenoxy)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 125038-39-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-cyanophenoxy)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 125038-40-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-methoxyphenoxy)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 125038-41-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(phenylmethyl)-2-[3-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 125038-42-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3,4-dichlorophenoxy)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 125038-43-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)





RN 125038-44-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-phenoxy-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 125038-46-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 125038-47-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[(4-chlorophenyl)methyl]-2-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)





RN 125038-49-5 CAPLUS

CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)



RN 125038-52-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)





RN 125038-53-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 125038-54-2 CAPLUS
CN Benzoic acid, 3-[[3-[[(phenylmethyl)amino]carbonyl]-2-pyridinyl]oxy]- (9CI) (CA INDEX NAME)



RN 125038-55-3 CAPLUS

CN Benzoic acid, 3-[[3-[[(phenylmethyl)amino]carbonyl]-2-pyridinyl]oxy]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 125038-56-4 CAPLUS
CN Benzoic acid, 3-[[3-[[(phenylmethyl)amino]carbonyl]-2-pyridinyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 125038-63-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[3-[(dimethylamino)carbonyl]phenoxy]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 125057-86-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[3-[(methylamino)carbonyl]phenoxy]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 27 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1987:636526 CAPLUS
DOCUMENT NUMBER: 107:236526
TITLE: Preparation and formulation of N-(ortho-substituted)benzyl-3-(trifluoromethyl)phenoxynicotinamides as herbicides
INVENTOR(S): Michaely, William J.
PATENT ASSIGNEE(S): Stauffer Chemical Co., USA
SOURCE: U.S., 6 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4692185	A	19870908	US 1986-818149	19860113

PRIORITY APPLN. INFO.: US 1986-818149 19860113
GI



I

AB Title compds. I (R = C1-4 alkyl, -haloalkyl, halo) were prepd. 2-(Trifluoromethylphenoxy)nicotinoyl chloride in CH2Cl2 was reacted with 2-FC6H4CH2NH2 to give I (R = F) (II) in 67% yield in a postemergence pre-flood application test II at 0.5 lb/ha controlled watergrass, annual morning-glory, and sesbania 90% without injury to rice. Compns. contg. I are given.

IT **111487-84-4P 111487-85-5P 111487-86-6P**
111487-87-7P 111522-92-0P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as herbicide)

RN 111487-84-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[(2-bromophenyl)methyl]-2-[3-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)





RN 111487-85-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[(2-methylphenyl)methyl]-2-[3-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)





RN 111487-86-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[(2-chlorophenyl)methyl]-2-[3-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)





RN 111487-87-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[(2-fluorophenyl)methyl]-2-[3-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)





RN 111522-92-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[3-(trifluoromethyl)phenoxy]-N-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)





L4 ANSWER 28 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1985:481535 CAPLUS
DOCUMENT NUMBER: 103:81535
TITLE: Inhibition of 3H-glibenclamide binding to sulfonylurea receptors by oral antidiabetics
AUTHOR(S): Geisen, K.; Hitzel, V.; Oekomonopoulos, R.; Puenter, J.; Weyer, R.; Summ, H. D.
CORPORATE SOURCE: Hoechst A.-G., Frankfurt/Main, D-6230/80, Fed. Rep. Ger.
SOURCE: Arzneimittel-Forschung (1985), 35(4), 707-12
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Specific binding of 3H-labeled glibenclamide (HB 419) (I) [10238-21-8] is obsd. with membranes from rat cerebral cortex and rat pancreatic .beta.-cell tumor. 3H-glibenclamide binding to sulfonylurea receptors is of high affinity, reversible, saturable, and can be displaced by oral antidiabetics of different structural types. Half-maximal inhibition of binding correlates with the hypoglycemic action of the compds.

IT **69151-77-5**
RL: BIOL (Biological study)
(glibenclamide binding to sulfonylurea receptors inhibition by, in brain and .beta.-cell tumor)

RN 69151-77-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



L4 ANSWER 29 OF 34 CAPLUS COPYRIGHT 2003 ACS.

ACCESSION NUMBER: 1981:532680 CAPLUS

DOCUMENT NUMBER: 95:132680

TITLE: N-Aryl-2-phenoxynicotinamide compounds and their herbicidal use

INVENTOR(S): Gutman, Arnold D.

PATENT ASSIGNEE(S): Stauffer Chemical Co. , USA

SOURCE: U.S., 7 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4270946	A	19810602	US 1979-80971	19791001
US 4327218	A	19820427	US 1980-210990	19801128

PRIORITY APPLN. INFO.: US 1979-80971 19791001

GI



I



II

AB The title amides (I; R, R1 = H, alkyl, haloalkyl, haloalkylthio, alkoxy, NO2, CN, halo; R2 = halo, alkyl, CF3, CO2Et; n = 0, 1), effective herbicides at 8 lb/acre, were prepd. Thus, 0.05 mol acid II was treated with Et3N.HCl and SOCl2 to give 66.7% acid chloride, which (0.011 mol) was treated with 3-O2NC6H4NH2 and Et3N in PhMe at <35.degree. to give 73.3% I (R = NO2, R1 = H, R2 = CF3, n = 0). Similarly prepd. were 47 addnl. I.

IT **78863-77-1P 78863-82-8P 78863-83-9P**
78863-88-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and herbicidal activity of)

RN 78863-77-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-chlorophenoxy)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 78863-82-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-bromophenoxy)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 78863-83-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-methylphenoxy)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 78863-88-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-(3-ethylphenoxy)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 30 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1979:523653 CAPLUS
DOCUMENT NUMBER: 91:123653
TITLE: Study of naphthyridines. 10. Synthesis and ionization constants of 10-(alkylamino)benzo[b]-1,8-naphthyridines
AUTHOR(S): Mikhalev, A. I.; Chesnokov, V. P.; Konshin, M. E.
CORPORATE SOURCE: Perm. Farm. Inst., Perm, 614600, USSR
SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1979), (6), 799-801
CODEN: KGSSAQ; ISSN: 0453-8234
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI



AB Cyclization of anilinopyridines I (R = Pr, Bu, isopentyl, PhCH2; R1 = Me, MeO) with POCl3 gave 60-73% title naphthyridines II. The pKa1 of II were 8.50-8.74 .+-. 0.02-0.04.
IT **65423-32-7 65423-36-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclization of)
RN 65423-32-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(4-methylphenyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 65423-36-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(4-methoxyphenyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 31 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1979:103843 CAPLUS
DOCUMENT NUMBER: 90:103843
TITLE: Benzenesulfonylureas
INVENTOR(S): Hitzel, Volker; Weyer, Rudi; Pfaff, Werner; Geisen, Karl
PATENT ASSIGNEE(S): Hoechst A.-G., Fed. Rep. Ger.
SOURCE: Ger. Offen., 15 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2720926	A1	19781123	DE 1977-2720926	19770510
DE 2720926	C2	19830217		
ES 469454	A1	19790816	ES 1978-469454	19780504
FI 7801451	A	19781111	FI 1978-1451	19780508
US 4157395	A	19790605	US 1978-903548	19780508
IL 54660	A1	19811130	IL 1978-54660	19780508
CH 637119	A	19830715	CH 1978-4988	19780508
DK 7802032	A	19781111	DK 1978-2032	19780509
NO 7801637	A	19781113	NO 1978-1637	19780509
NL 7804988	A	19781114	NL 1978-4988	19780509
ZA 7802629	A	19790425	ZA 1978-2629	19780509
AU 7835942	A1	19791115	AU 1978-35942	19780509
AU 515711	B2	19810416		
AT 7803354	A	19810815	AT 1978-3354	19780509
AT 366366	B	19820413		
GB 1599250	A	19810930	GB 1978-18454	19780509
BE 866928	A1	19781110	BE 1978-187577	19780510
SE 7805357	A	19781111	SE 1978-5357	19780510
FR 2390432	A1	19781208	FR 1978-13836	19780510

FR 2390432	B1	19811127		
JP 53141278	A2	19781208	JP 1978-55444	19780510
HU 20571	O	19810828	HU 1978-HO2073	19780510
HU 178247	P	19820428		
ES 477303	A1	19790701	ES 1979-477303	19790131
ES 477304	A1	19790701	ES 1979-477304	19790131
ES 477301	A1	19790701	ES 1979-477301	19790131
ES 477300	A1	19790701	ES 1979-477300	19790131
ES 477302	A1	19790701	ES 1979-477302	19790131
AT 8101545	A	19810915	AT 1981-1545	19810402
AT 366669	B	19820426		
AT 8101546	A	19810915	AT 1981-1546	19810402
AT 366670	B	19820426		
AT 8101544	A	19840415	AT 1981-1544	19810402
AT 8101547	A	19840415	AT 1981-1547	19810402
AT 8101548	A	19840415	AT 1981-1548	19810402
PRIORITY APPLN. INFO.:			DE 1977-2720926	19770510
			AT 1978-3345	19780509
			AT 1978-3354	19780509

GI



I

AB The benzenesulfonylureas I (R = C1-6 alkyl, cycloalkyl, alkylcycloalkyl, cycloalkenyl, alkylcycloalkenyl; R1 = C3-8 alkyl, C5-9 cycloalkyl, Ph, substituted Ph, phenylalkyl, substituted phenylalkyl, R2 = H, alkyl, alkoxy, halo, X = C2-3 alkylene) were prepd. as antidiabetics (no data). Thus, 4-[2-(2-butoxy-5-chloronicotinamido)ethyl]benzenesulfonamide was treated with cyclohexyl isocyanate to give I (R = cyclohexyl, R1 = Bu, R2 = 5-Cl, X = CH2CH2).

IT **69151-77-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 69151-77-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)



L4 ANSWER 32 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER:	1979:6251 CAPLUS
DOCUMENT NUMBER:	90:6251
TITLE:	Benzoic acid and its derivatives
INVENTOR(S):	Hitzel, Volker; Weyer, Rudi; Geisen, Karl; Pfaff, Werner
PATENT ASSIGNEE(S):	Hoechst A.-G., Fed. Rep. Ger.
SOURCE:	Ger. Offen., 20 pp. Addn. to Ger. Offen. 2,500,157.

CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2706977	A1	19780824	DE 1977-2706977	19770218
ES 466910	A1	19781001	ES 1978-466910	19780213
FR 2381028	A1	19780915	FR 1978-4116	19780214
FR 2381028	B1	19801024		
FI 7800491	A	19780819	FI 1978-491	19780215
CH 645625	A	19841015	CH 1978-1659	19780215
US 4181658	A	19800101	US 1978-878602	19780216
SE 7801885	A	19780818	SE 1978-1885	19780217
DK 7800712	A	19780819	DK 1978-712	19780217
NO 7800558	A	19780821	NO 1978-558	19780217
NL 7801859	A	19780822	NL 1978-1859	19780217
ZA 7800946	A	19790131	ZA 1978-946	19780217
AU 7833376	A1	19790823	AU 1978-33376	19780217
AT 7801181	A	19800615	AT 1978-1181	19780217
AT 360534	B	19810112		
CA 1113473	A1	19811201	CA 1978-297158	19780217
JP 53103477	A2	19780908	JP 1978-17140	19780218
BE 864112	A1	19780821	BE 1978-185297	19780220
GB 1601195	A	19811028	GB 1978-6598	19780220
AT 8000448	A	19800615	AT 1980-448	19800128
AT 360540	B	19810112		
AT 8000449	A	19800615	AT 1980-449	19800128
AT 360541	B	19810112		

PRIORITY APPLN. INFO.: DE 1977-2706977 19770218
AT 1978-1181 19780217

GI





I





II

AB Antidiabetic (no data) pyridinecarboxamides I (R = Q, Q1; R1, R4 = H, Cl, Br; R2 = H, ester, salt; R3 = H, halogen, alkyl, alkoxy, alkoxyalkoxy, alkenyloxy; R5 = C2-8 alkyl, aralkyl optionally substituted by alkyl, halogen, Ph, C5-8 cycloalkyl; R6 = C5-8 alkyl, aralkyl optionally

substituted by alkyl or halogen, Ph, C5-8 cycloalkyl; n = 0-3) were prepd. Thus, 2-butoxynicotinic acid was treated with ClCO2Me and 4-H2NCH2CH2C6H4CO2Et.HCl to give II (R2 = Et), which was hydrolyzed to II (R2 = H).

IT **68359-05-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 68359-05-7 CAPLUS

CN Benzoic acid, 4-[2-[[(2-phenoxy-3-pyridinyl)carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 33 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1978:69080 CAPLUS

DOCUMENT NUMBER: 88:69080

TITLE: Synthesis and biological activity of substituted 2-arylaminonicotinic acids

AUTHOR(S): Mikhalev, A. I.; Kudryashova, V. K.; Zalesov, V. S.; Chesnokov, V. P.; Konshin, M. E.

CORPORATE SOURCE: Perm. Farm. Inst., Perm, USSR

SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1977), 11(11), 78-81
CODEN: KHFZAN; ISSN: 0023-1134

DOCUMENT TYPE: Journal

LANGUAGE: Russian

GI



I

AB Eight substituted 2-arylaminonicotinic acids (I) were synthesized by treating the alkylamide of 2-chloronicotinic acid with arylamine, and(or) by treating Me 2-(p-anisidino)nicotinate with alkylamine. 2-Chloronicotinic acid isoamylamide [65423-27-0] and 2-chloronicotinic acid benzylamide [65423-28-1] were also prepd. LD50 values were given for all 10 compds. and anticonvulsant activity for 4 of the compds. was detd. in mice. 2-Chloronicotinic acid benzylamide had the greatest biol. activity inhibiting electroschock- and corazole-induced convulsions by 50% at 145 and 110 mg/kg, i.p., resp.; the duration of biol. activity in these 2 cases was 5.4 and 7.1 h, resp.

IT **65423-36-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and anticonvulsant activity of)

RN 65423-36-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(4-methoxyphenyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT **65423-32-7P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and toxicity of)
RN 65423-32-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(4-methylphenyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 34 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1976:4816 CAPLUS
DOCUMENT NUMBER: 84:4816
TITLE: 2-(Substituted amino)nicotinamides
INVENTOR(S): Noda, Kanji; Nakagawa, Akira; Ide, Hiroyuki
PATENT ASSIGNEE(S): Hisamitsu Pharmaceutical Co., Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 50082075	A2	19750703	JP 1973-131523	19731120
JP 61002667	B4	19860127		

PRIORITY APPLN. INFO.: JP 1973-131523 19731120
GI For diagram(s), see printed CA Issue.
AB 2-Aminonicotinamides I (R1 = aryl, cycloalkyl, aralkyl; R2 = H, lower alkyl, substituted lower alkyl, unsatd. lower alkyl) are prepd. by treating 2-aminonicotinic acids II or their reactive derivs. with amines R2NH2. I have antiinflammatory and analgesic effects (no data). Thus, 3 g 2-(m-trifluoromethylanilino)nicotinoyl chloride in THF were treated with NH3 to give 2.6 g I (R1 = C6H4CF3-m, R2 = H). Among 96 more I prepd. were (R1, R2 given): C6H4CF3-m, CH2CH2OH; C6H4CF3-m, Bu; C6H4Br-m, iso-Pr; C6H3Cl2-3,4, allyl.
IT **57520-86-2P 57520-87-3P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 57520-86-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(3-nitrophenyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 57520-87-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(3-nitrophenyl)amino]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 14:23:26 ON 13 MAY 2003)

FILE 'REGISTRY' ENTERED AT 14:23:35 ON 13 MAY 2003
L1 STRUCTURE UPLOADED
L2 12 S L1
L3 413 S L1 FULL

FILE 'CAPLUS' ENTERED AT 14:24:26 ON 13 MAY 2003
L4 34 S L3

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.